nicotine has been researched along with quinoxalines in 256 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (0.78) | 18.7374 |
| 1990's | 5 (1.95) | 18.2507 |
| 2000's | 100 (39.06) | 29.6817 |
| 2010's | 141 (55.08) | 24.3611 |
| 2020's | 8 (3.13) | 2.80 |
| Authors | Studies |
|---|---|
| Franco-Cereceda, A; Lou, YP; Lundberg, JM | 1 |
| Brunnemann, KD; Hornby, AP; Stich, HF | 1 |
| Neurath, G | 1 |
| Changeux, JP; Vidal, C | 1 |
| Connor, HE; O'Shaughnessy, CT | 1 |
| Kauer, JA; Williams, JH | 1 |
| Catalin, D; Miolan, JP; Niel, JP; Quinson, N | 1 |
| Clouse, WD; Hurt, RD; Miller, VM; Rud, KS | 1 |
| Mansvelder, HD; McGehee, DS | 1 |
| Cherubini, E; Maggi, L; Sher, E | 1 |
| Keath, JR; Mansvelder, HD; McGehee, DS | 1 |
| Jeong, MS; Kim, CJ; Kim, KW; Park, EY; Park, JW; Shin, BS; Shin, MS; Woo, RS; Zhao, RJ | 1 |
| Amtage, F; Birthelmer, A; Cassel, JC; Ehret, A; Förster, S; Jackisch, R; Jeltsch, H; Lehmann, O | 1 |
| Gasparini, F; Kenny, PJ; Markou, A | 1 |
| Cebere, A; Cebers, G; Kosowski, AR; Liljequist, S; Swanhagen, AC | 1 |
| Kanno, T; Nagata, T; Nishizaki, T; Tanaka, A; Yaguchi, T; Yamamoto, S | 1 |
| Bruno, JP; Nelson, CL; Sarter, M | 1 |
| Camarelles Guillem, F | 1 |
| Hamaue, N; Jia, Y; Sumikawa, K; Yamazaki, Y | 1 |
| Corelli, RL; Hudmon, KS | 1 |
| Burstein, AH; Clark, DJ; Faessel, HM; Gibbs, MA; Rohrbacher, K; Stolar, M | 1 |
| Mogg, A; Peacey, E; Pullar, IA; Smith, JW; Szekeres, P; Tafi, E; Tricklebank, M | 1 |
| Fujii, S; Jia, Y; Sumikawa, K; Yamazaki, Y | 1 |
| Dimoulas, P; Mills, EJ; Wilson, K; Wu, P | 1 |
| Chambers, LK; Coe, JW; Glowa, J; Hurst, RS; Lebel, LA; Lu, Y; Mansbach, RS; Mather, RJ; Rollema, H; Rovetti, CC; Sands, SB; Schaeffer, E; Schulz, DW; Tingley, FD; Williams, KE | 1 |
| Siu, EC; Tyndale, RF | 1 |
| Cahill, K; Lancaster, T; Stead, LF | 5 |
| Dar, MS; Smith, AD | 1 |
| Frishman, WH | 1 |
| Oberpichler-Schwenk, H | 1 |
| Crane, R | 1 |
| Garwood, CL; Potts, LA | 1 |
| Freedman, R | 1 |
| Croghan, E | 1 |
| Lerman, C; Patterson, F; Schnoll, RA | 1 |
| Doggrell, SA | 1 |
| Hoogendoorn, M; Rutten-van Mölken, MP; Welsing, P | 1 |
| George, TP; Le Foll, B | 1 |
| Milbrandt, A; Ratcliffe, M; Smith, R; Spirling, LI; Stapleton, JA; Sutherland, G; Watson, L | 1 |
| Cohen, AF; Dubois, EA; van Bronswijk, H; Zitman, FG | 1 |
| Andrews, JO; Bennett, SM; Heath, JH | 1 |
| Cahill, K; Lancaster, T; Stead, L | 2 |
| Baker, CL; Bushmakin, AG; Cappelleri, JC; West, R | 1 |
| Cooley, ME; Murphy, M; Sarna, L; Sipples, RL | 1 |
| Aubin, HJ; Billing, CB; Bobak, A; Britton, JR; Gong, J; Oncken, C; Reeves, KR; Williams, KE | 1 |
| Benowitz, NL | 2 |
| Stapleton, JA | 1 |
| Wonnacott, S | 1 |
| Decker, MW; Man, K; Parikh, V; Sarter, M | 1 |
| Carlezon, WA; Chartoff, E; Kenny, PJ; Markou, A; Roberto, M | 1 |
| Crawford, JT; Goldenberg, RL; Tolosa, JE | 1 |
| Brees, DJ; Cai, JH; Elwell, MR; Finkelstein, MB; Jakowski, AB; Sands, SB; Shen, AC; Tingley, FD | 1 |
| Baker, C; Boler, A; Howard, P; Knight, C | 1 |
| Bölcskei, PL; Walden, K | 1 |
| Tønnesen, P | 2 |
| Bélisle, P; Eisenberg, MJ; Filion, KB; Gervais, A; Joseph, L; Mottillo, S; O'Loughlin, J; Paradis, G; Pilote, L; Rinfret, S; Yavin, D | 1 |
| Rose, JE | 2 |
| Bhowmik, A; Hillman, T; Rajakulasingam, K | 1 |
| Ferguson, SG; Shiffman, S | 1 |
| Reus, VI; Smith, BJ | 1 |
| Filip, M; McCreary, AC; Przegaliński, E; Stefański, R; Zaniewska, M | 1 |
| Greenshaw, AJ; Hayes, DJ; Mosher, TM | 1 |
| Carroll, FI; Corrigall, WA; LeSage, MG; Ross, JT; Shelley, D | 1 |
| Bader, P; McDonald, P; Selby, P | 1 |
| Hering, T | 2 |
| Schunack, W | 1 |
| Brace, V; Danielian, P; Rore, C; Williams, D | 1 |
| Ebbert, JO; Hays, JT | 2 |
| Bardo, MT; Crooks, PA; Dwoskin, LP; Joyce, BM; Neugebauer, NM; Pivavarchyk, M; Zhang, Z; Zheng, G | 1 |
| Peiffer, G | 1 |
| Ericson, M; Löf, E; Söderpalm, B; Stomberg, R | 1 |
| McEwen, A; West, R | 1 |
| Aveyard, P; Hajek, P; Inglis, J; Parsons, AC; Shraim, M | 1 |
| Einarson, A; Riordan, S | 1 |
| Good, CH; Lupica, CR | 1 |
| Florek, E; Piekoszewski, W | 1 |
| Arora, G; Jain, M; Talwar, A | 1 |
| Cornwell, J; Davis, JM; Gupta, S; Lajtha, A; Lindenmayer, JP; Noth, K; Sershen, H; Smith, RC | 1 |
| Ebbert, JO | 1 |
| Burke, MV; Ebbert, JO; Hays, JT; Hurt, RD | 1 |
| Ferguson, SG; Gritz, ER; Henningfield, JE; Shiffman, S | 1 |
| Ashby, CR; Callahan, PM; Gardner, EL; Li, X; Spiller, K; Tehim, A; Xi, ZX | 1 |
| Cryan, JF; Flynn, RA; Glynn, DA; Kennedy, MP; Kent, P | 1 |
| Laniado-Laborín, R | 2 |
| George, TP; Lising-Enriquez, K | 1 |
| Bau, CH; Bizarro, L; Dobler, CJ; Kortmann, GL | 1 |
| Heimlich, L; Steinberg, ML; Williams, JM | 1 |
| Aubin, HJ; Benhaddi, H; Bolin, K; de Nigris, E; Marbaix, S; Mork, AC; Wilson, K | 1 |
| Deissenrieder, F; Groneberg, D; Kusma, B; Mache, S; Quarcoo, D; Welte, T | 1 |
| Keiding, H | 1 |
| Herman, AI; Mooney, M; Sofuoglu, M; Waters, AJ | 1 |
| Maritz, GS | 1 |
| Annemans, L; Bartsch, P; Marbaix, S; Nackaerts, K; Prignot, J | 1 |
| Kranzler, HR; Oncken, CA | 1 |
| Tonstad, S | 1 |
| Davies, C; Gunnell, D; Irvine, D; Martin, RM; Wise, L | 1 |
| Dufour, E; Gardier, AM; Maskos, U; Pons, S; Reperant, C; Rollema, H | 1 |
| Batra, A; Friederich, HM | 1 |
| Mead, AN; O'Connor, EC; Parker, D; Rollema, H | 1 |
| Corelli, RL; Hudmon, KS; Prokhorov, AV | 1 |
| Huang, LT; Lodge, D; Sherwood, JL; Sun, YJ; Wang, Y | 1 |
| Keating, GM; Lyseng-Williamson, KA | 1 |
| Noda, K; Saku, K; Tsukahara, H | 1 |
| Biala, G; Budzynska, B; Staniak, N | 1 |
| Barr, JD; Bevins, RA; Murray, JE; Reichel, CM | 1 |
| Costa, E; Davis, JM; Guidotti, A; Lajtha, A; Maloku, E; Sershen, H; Smith, RC; Zhubi, A | 1 |
| Ainamo, A; Binnie, VI; Carr, AB; Fundak, A; Koeber, A; Koerber, A; Needleman, IG; Ohrn, K; Rosseel, J | 1 |
| Beck, HN; Biazzo, LL; Campbell, SL; Froshaug, DB; Harwell, TS; Haugland, C; Helgerson, SD | 1 |
| Frey, JM; Jepson, C; Lerman, C; Patterson, F; Phillips, JM; Rudnick, ND; Siegel, SJ; Strasser, AA; Turetsky, BI | 1 |
| Blendy, JA; Castellano, LM; Turner, JR | 2 |
| Biala, G; Staniak, N | 1 |
| Hizue, M; Ishibashi, T; Nomura, S | 1 |
| Bhat, A; Crain, D | 1 |
| Chengappa, KN; Fonte, CA; Jain, A; Lerman, C; Mercincavage, M; Perkins, KA; Stitzer, ML | 1 |
| Ioannides-Demos, LL; McNeil, JJ; Piccenna, L | 1 |
| Lund, KE; McNeill, A; Scheffels, J | 1 |
| Herman, AI; Sofuoglu, M | 1 |
| Ruff, P | 1 |
| Zeller, A | 1 |
| von Garnier, C | 1 |
| Ayesta Ayesta, FJ; Minué Lorenzo, C; Olano Espinosa, E | 1 |
| Carroll, FI; Damaj, MI; George, O; Koob, GF; Lloyd, A | 1 |
| Bover, MT; Foulds, J; Richardson, DL; Schmelzer, AC; Steinberg, MB; Williams, JM | 1 |
| Gnegy, ME; Jutkiewicz, EM; Kim, MN; Zhang, M | 1 |
| Johnson, TS | 1 |
| Cesario, A; Galetta, D; Granone, P; Greenberg, DS; Margaritora, S; Russo, P; Rutella, S; Spaggiari, L; Veronesi, G | 1 |
| Balmford, J; Borland, R; Cummings, KM; Hammond, D | 1 |
| Cunningham, CS; McMahon, LR | 2 |
| Weinsier, ST | 1 |
| Al Rubaiy, SA; Bloom, SA; Guendisch, D; Papke, RL; Trocmé-Thibierge, C | 1 |
| Ebbert, J; Erwin, PJ; Montori, VM; Stead, LF | 1 |
| De Vries, TJ; De Vries, W; Pattij, T; Riga, D; Schetters, D; Schoffelmeer, AN; Stegeman, M; van Mourik, Y; Wouda, JA | 1 |
| Grief, SN | 1 |
| Dong, E; Guidotti, A; Kadriu, B; Maloku, E; Pibiri, F; Satta, R; Zhubi, A | 1 |
| Díaz Cerezo, S; Martí Sánchez, B; Navarro Artieda, R; Sanz De Burgoa, V; Sicras Mainar, A | 1 |
| Bartlett, SE; Bito-Onon, JJ; Chatterjee, S; Holgate, J; Simms, JA | 1 |
| Coleman, T; Huang, Y; Langley, TE; Lewis, S; McNeill, A; Szatkowski, L | 1 |
| Gur, RC; Lerman, C; Loughead, J; O'Donnell, GP; Ray, R; Ruparel, K; Senecal, N; Siegel, S; Wileyto, EP | 1 |
| Simon, JA | 1 |
| Aubin, HJ; Karila, L; Reynaud, M | 1 |
| Bircher, R; Chen, W; DiFranza, JR; Heffernan, M; Huang, W; King, J; Rane, P; Shields, J | 1 |
| Agboola, S; Coleman, T; Leonardi-Bee, J; McNeill, A; Taylor, M | 1 |
| Coleman, T; Lewis, S; McNeill, A; Szatkowski, L | 1 |
| Foulds, J; Gandhi, KK; Steinberg, MB; Steinberg, ML; Ulpe, R; Williams, JM | 1 |
| Belcon, AL | 1 |
| Marti, J | 1 |
| Brooks, EA; Jutkiewicz, EM; Kynaston, AD; Rice, KC; Woods, JH | 1 |
| Czoty, PW; Gould, RW; Nader, MA; Nader, SH | 1 |
| Bell, KA; Chen, CK; McQuiston, AR; Shim, H | 1 |
| Kadokura, Y; Kano, M; Kushihashi, Y; Saito, H; Shino, M; Suzaki, H; Suzuki, M; Takiguchi, S; Yamada, Y | 1 |
| Barnes, C; Chakraborty-Chatterjee, M; Gamaleddin, I; Goldberg, SR; Khaled, M; Le Foll, B; Lev-Ran, S; Pushparaj, A; Yan, Y | 1 |
| Baker, TB; Fiore, MC | 1 |
| Caggiula, AR; Donny, EC; Levin, ME; Palmatier, MI; Sved, AF; Weaver, MT | 1 |
| Ansermot, N; Choong, E; Cornuz, J; Dobrinas, M; Eap, CB; Noetzli, M | 1 |
| Furberg, CD; Glenmullen, J; Maltsberger, JT; Moore, TJ; Singh, S | 1 |
| Grady, SR; Marks, MJ; O'Neill, HC; Ortiz, NC | 1 |
| Ammerman, S; Bailey, SR; Crew, EE; Killen, JD; Riske, EC; Robinson, TN | 1 |
| Aveyard, P; Farley, AC; Hajek, P; Lycett, D | 1 |
| Schuurmans, MM; Zellweger, JP | 1 |
| Azar, MR; Cohen, A; Fox, BS; George, O; Goeders, NE; Koob, GF | 1 |
| Cunningham, CS; Javors, MA; McMahon, LR | 1 |
| Etter, JF; Schneider, NG | 1 |
| Bordia, T; Chin, M; Hrachova, M; McIntosh, JM; Quik, M | 1 |
| Gallagher, T; Haseler, CA; Rucktooa, P; Sixma, TK; Smit, AB; van Elk, R | 1 |
| Papke, RL; Stokes, C | 1 |
| Browning, KK; Diaz, P; Ferketich, AK; Koletar, SL; Lu, B; Reynolds, NR; Wewers, ME | 1 |
| Ashare, RL; Blair, IA; Leone, F; Mesaros, AC; Strasser, AA; Tang, KZ | 1 |
| Akk, G; Esch, C; Herder, P; Laughlin, JR; Li, P; Stitzel, JA; Tammimäki, A | 1 |
| Blendy, JA; Cousins, V; Hussmann, GP; Kellar, KJ; Levin, ED; Lomazzo, E; Perry, DC; Rezvani, AH; Turner, JR; Venkatesh, R; Wolfe, BB; Xiao, Y; Yasuda, RP | 1 |
| Garg, PK; Garg, S; Gould, RW; Nader, MA | 1 |
| Holloway, AC; Nicholson, CJ; Raha, S; Woynillowicz, AK | 1 |
| Mikkelsen, K; Tønnesen, P | 1 |
| Anthony, JC; Behm, FM; Eaton, WW; Fisher, C; Ialongo, N; Musci, R; Rose, JE; Storr, CL; Uhl, GR; Walther, D | 1 |
| Almgren, MM; Clark, KJ; Stroman, RT; Wynn, WP | 1 |
| Biała, G; Budzyńska, B; Kruk-Słomka, M | 1 |
| Baker, TB; Benowitz, NL; Bergen, AW; Conti, DV; Edlund, CK; Hall, S; Javitz, HS; Krasnow, R; Kwok, PY; Lee, W; Lerman, C; Liu, J; Michel, M; Nishita, D; Swan, GE; Tyndale, RF | 1 |
| Chen, SR; Cheng, PW; Cheng, WH; Hong, LZ; Tseng, CJ; Wang, LL | 1 |
| Dixon-McDougall, T; Nowak, C; Pereira, S; Qian, C; Sellings, L; Tyndale, RF; van der Kooy, D; Zhao, B | 1 |
| Damborsky, JC; DuBois, DW; Fincher, AS; Frye, GD; Winzer-Serhan, UH | 1 |
| Milnerowicz, H; Sliwińska-Mossoń, M; Zieleń, I | 1 |
| Porwal, M; Tsoi, DT; Webster, AC | 1 |
| Bloem, B; Mansvelder, HD; Poorthuis, RB; Verhoog, MB | 1 |
| Carroll, AJ; Hong, LE; Ross, TJ; Salmeron, BJ; Stein, EA; Sutherland, MT | 1 |
| Brown, VL; Cinciripini, PM; Engelmann, JM; Karam-Hage, M; Lam, C; Minnix, JA; Robinson, JD; Versace, F; Wetter, DW | 1 |
| Blendy, JA; Carlson, GC; Gould, TJ; Poole, RL; Turner, JR; Wilkinson, DS | 1 |
| Berg, A; Foulds, J; Franzon, M; Galaznik, A; Hughes, JR; Russ, C; Yu, CR; Zou, KH | 1 |
| Antilla, JC; Bickford, PC; Engberg, ME; Hudson, CE; Kang, CW; Lambert, CS; Philpot, RM; Rowell, PP; Wecker, L; Zesiewicz, TA | 1 |
| Fagerström, KO; Jiménez-Ruiz, CA | 1 |
| Brasic, JR; Chamroonrat, W; Dannals, RF; Gao, Y; Gean, EG; Horti, AG; Kim, J; Kuwabara, H; Mathur, A; McCaul, ME; Valentine, H; Wand, G; Willis, W; Wong, DF | 1 |
| Brown, J; Kotz, D; West, R | 2 |
| Hajek, P; Hartmann-Boyce, J; Jarvis, M; Lancaster, T; Stead, LF; West, R | 1 |
| Alexander, JC; Bruijnzeel, AW; Igari, M; Ji, Y; Papke, RL; Qi, X | 1 |
| Kaakkola, S; Tuominen, R | 1 |
| Dow, WH; Rungruanghiranya, S; White, JS | 1 |
| Checa-Andrés, MD; Esparza-Martín, N; García-Cantón, C; Guerra-Rodríguez, R; Ramírez-Puga, A; Suria-González, S | 1 |
| Goutier, W; Kloeze, MB; McCreary, AC | 1 |
| Carroll, FI; Fivel, PA; Kohut, SJ; Mello, NK | 1 |
| Eapen, S; Mills, EJ; Prochaska, JJ; Thorlund, K; Wu, P | 1 |
| Bertrand, D; Hurst, RS; Lee, TC; Rollema, H; Russ, C | 1 |
| Blendy, JA; DeDominicis, KE; Forcelli, PA; Hussmann, GP; Kellar, KJ; Klehm, J; Lindstrom, J; Richardson, JR; Sahibzada, N; Turner, JR; Wolfe, BB; Xiao, Y; Yasuda, RP | 1 |
| Gupta, T; Jain, R; Majumder, P | 1 |
| Cieślewicz, A; Jabłecka, A; Korzeniowska, K | 1 |
| Daughton, DM; Rennard, SI | 1 |
| Buyukuysal, S; Coskun, AS; Goktalay, G; Goktalay, T; Kayir, H; Uslu, G; Uzbay, T; Yorgancioglu, A | 1 |
| Ebbert, JO; Elrashidi, MY | 1 |
| Argue, DP; Cousin, MA; Ebbert, JO; Ekker, SC; Klee, EW; Urban, MD; Wiinamaki, AR | 1 |
| Møller, AM; Thomsen, T; Villebro, N | 1 |
| Andrea, D; Braida, D; Cannazza, G; Clementi, F; Fasoli, F; Gotti, C; Manfredi, I; Papke, RL; Ponzoni, L; Pucci, L; Sala, M; Stokes, C | 1 |
| Arteaga, C; Brosky, G; Oh, P; Ranger, S; Raymond, V; Selby, P | 1 |
| Abdool-Gaffar, MS; Bateman, ED; Bruning, A; Emanuel, S; Esterhuizen, TM; Irusen, EM; Koegelenberg, CF; Noor, F; O'Brien, JA; Smith, C; van Zyl-Smit, RN | 1 |
| Faessel, HM; Gastonguay, MR; Lee, TC; Niaura, R; Ravva, P | 1 |
| Caggiula, AR; Donny, EC; Levin, ME; Palmatier, MI; Schassburger, RL; Sved, AF; Weaver, MT | 1 |
| Fisher, DC; Fletcher, PJ; Guy, EG; Higgins, GA | 1 |
| Baena, A; Masuet-Aumatell, C; Morchon, S; Ramon, JM | 1 |
| Steurer, J | 1 |
| Abe, S; Imaizumi, S; Kawachi, E; Matsuo, Y; Miura, S; Noda, K; Saku, K; Shimizu, T; Suematsu, Y; Takata, K; Tsukahara, H; Uehara, Y; Yahiro, E; Zhang, B | 1 |
| Hogarth, L; Panlilio, LV; Shoaib, M | 1 |
| Baker, NL; Carpenter, MJ; Gray, KM; Hartwell, KJ; McClure, EA; Ramakrishnan, V; Saladin, ME | 1 |
| Borland, R; Brady, K; Carpenter, MJ; Cummings, KM; Fong, GT; Hartwell, K; Hyland, A; Kasza, KA; McKee, SA; Smith, PH | 1 |
| He, Y; Sun, S; Wu, L; Zeng, J | 1 |
| Chen, K; Nakauchi, S; Su, H; Sumikawa, K; Tanimoto, S | 1 |
| Ebbert, JO; Elrashidi, MY; Stead, LF | 1 |
| Kato, T; Kawano, T; Sato, H; Toyoda, H; Yin, DX | 1 |
| Brath, H; Fasching, P; Kaser, S; Tatschl, C | 1 |
| Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
| Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y | 1 |
| Ashare, RL; Bauer, AM; Flitter, A; Gross, R; Hitsman, B; Hosie Quinn, M; Leone, FT; Lubitz, SF; Schnoll, R | 1 |
| Antoniu, SA; Buculei, I; Crisan Dabija, R; Mihaltan, F; Trofor, AC | 1 |
| Amchova, P; Ruda-Kucerova, J; Siska, F; Tizabi, Y | 1 |
| Abramson, MJ; Bonevski, B; George, J; Gobarani, RK; Ilomäki, J; Wood, S | 1 |
| Humair, JP; Papachristou, C | 1 |
| Barrett, ST; Bevins, RA; Dwoskin, LP; Huynh, YW; Thompson, BM; Tracy, ME | 1 |
| Budzyńska, B; Chałas, R; Maciąg, M; Rahnama-Hezavah, M; Stachurski, P; Świątkowska, A; Świątkowski, W; Tylżanowski, P | 1 |
84 review(s) available for nicotine and quinoxalines
| Article | Year |
|---|---|
[Nitrogen compounds of tobacco smoke].
Topics: Acridines; Alkaloids; Alkanes; Amines; Amino Acids; Aniline Compounds; Carbazoles; Cyanates; Indoles; Isoquinolines; Ketones; Niacinamide; Nicotiana; Nicotine; Nicotinic Acids; Nitriles; Nitrites; Nitrosamines; Piperidines; Plants, Toxic; Pyrazines; Pyridines; Pyrroles; Pyrrolidines; Quinolines; Quinoxalines; Smoking | 1969 |
Pharmacologic interventions for smoking cessation.
Topics: Administration, Cutaneous; Administration, Inhalation; Antidepressive Agents, Second-Generation; Benzazepines; Bupropion; Chewing Gum; Clonidine; Critical Care; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Nicotine; Nicotinic Agonists; Nortriptyline; Nurse's Role; Patient Education as Topic; Patient Selection; Phytotherapy; Piperidines; Pyrazoles; Quinoxalines; Rimonabant; Smoking Cessation; Smoking Prevention; United States; United States Food and Drug Administration; Varenicline | 2006 |
Effectiveness of smoking cessation therapies: a systematic review and meta-analysis.
Topics: Benzazepines; Bupropion; Humans; Nicotine; Quinoxalines; Smoking Cessation; Treatment Outcome; Varenicline | 2006 |
Non-nicotinic therapies for smoking cessation.
Topics: Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Drugs, Investigational; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Tobacco Use Disorder; Varenicline | 2007 |
Nicotine receptor partial agonists for smoking cessation.
Topics: Alkaloids; Azocines; Benzazepines; Humans; Nicotine; Nicotinic Agonists; Quinolizines; Quinoxalines; Randomized Controlled Trials as Topic; Smoking Cessation; Varenicline | 2007 |
Smoking cessation pharmacotherapy--nicotine and non-nicotine preparations.
Topics: Administration, Cutaneous; Administration, Inhalation; Benzazepines; Bupropion; Chewing Gum; Clonidine; Coronary Artery Disease; Humans; Monoamine Oxidase Inhibitors; Nicotine; Nortriptyline; Piperidines; Pyrazoles; Quinoxalines; Receptors, Nicotinic; Rimonabant; Selective Serotonin Reuptake Inhibitors; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Disorder; Tobacco, Smokeless; Varenicline | 2007 |
The most addictive drug, the most deadly substance: smoking cessation tactics for the busy clinician.
Topics: Age Factors; Benzazepines; Bupropion; Complementary Therapies; Dopamine Uptake Inhibitors; Dosage Forms; Humans; Nicotine; Nicotinic Agonists; Physician's Role; Primary Health Care; Quinoxalines; Referral and Consultation; Smoking Cessation; Tobacco Use Disorder; Varenicline | 2007 |
Varenicline: the newest agent for smoking cessation.
Topics: Animals; Benzazepines; Clinical Trials, Phase III as Topic; Drug Interactions; Humans; Nicotine; Quinoxalines; Receptors, Cholinergic; Smoking Cessation; Varenicline | 2007 |
Optimizing on smoke free legislation making the most of the opportunity.
Topics: Benzazepines; Bupropion; Decision Trees; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Health Services Needs and Demand; Humans; Nicotine; Nicotinic Agonists; Nurse's Role; Patient Care Planning; Patient Education as Topic; Practice Guidelines as Topic; Public Facilities; Quinoxalines; Smoking; Smoking Cessation; Smoking Prevention; Social Support; United Kingdom; Varenicline | 2007 |
Treating tobacco dependence in women.
Topics: Benzazepines; Bupropion; Counseling; Dopamine Uptake Inhibitors; Female; Humans; Lung Neoplasms; Nicotine; Nicotinic Agonists; Quinoxalines; Risk Reduction Behavior; Smoking; Smoking Cessation; Smoking Prevention; Tobacco Use Disorder; United States; Varenicline; Women's Health | 2007 |
Which is the best primary medication for long-term smoking cessation--nicotine replacement therapy, bupropion or varenicline?
Topics: Benzazepines; Bupropion; Combined Modality Therapy; Counseling; Dopamine Uptake Inhibitors; Drug Administration Routes; Drug Partial Agonism; Drug Therapy, Combination; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Time Factors; Treatment Outcome; Varenicline | 2007 |
Treatment of tobacco dependence: integrating recent progress into practice.
Topics: Behavior Therapy; Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Health Behavior; Health Policy; Humans; Nicotine; Nicotinic Agonists; Practice Guidelines as Topic; Quinoxalines; Tobacco Use Cessation; Tobacco Use Disorder; Varenicline | 2007 |
Breaking the ties of nicotine dependence.
Topics: Algorithms; Benzazepines; Bupropion; Decision Trees; Dopamine Uptake Inhibitors; Drug Costs; Evidence-Based Medicine; Global Health; Humans; Nicotine; Nicotinic Agonists; Nurse Practitioners; Nurse's Role; Nursing Assessment; Patient Acceptance of Health Care; Patient Care Planning; Patient Education as Topic; Practice Guidelines as Topic; Prevalence; Primary Health Care; Quinoxalines; Risk Factors; Smoking Cessation; Tobacco Use Disorder; Varenicline | 2007 |
An update on therapeutics for tobacco dependence.
Topics: Alkaloids; Anti-Anxiety Agents; Azocines; Benzazepines; Bupropion; Clinical Trials as Topic; Databases, Bibliographic; Humans; Nicotine; Nicotinic Agonists; Piperidines; Pyrazoles; Quinolizines; Quinoxalines; Review Literature as Topic; Rimonabant; Smoking; Smoking Cessation; Varenicline | 2008 |
Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt.
Topics: Adolescent; Adult; Affect; Aged; Benzazepines; Bupropion; Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Dopamine Uptake Inhibitors; Double-Blind Method; Follow-Up Studies; Humans; Middle Aged; Motivation; Multicenter Studies as Topic; Nicotine; Nicotinic Agonists; Quinoxalines; Randomized Controlled Trials as Topic; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Disorder; Varenicline | 2008 |
Smoking cessation and lung cancer: oncology nurses can make a difference.
Topics: Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Humans; Information Services; Lung Neoplasms; Nicotine; Oncology Nursing; Quinoxalines; Smoking; Smoking Cessation; Varenicline | 2008 |
Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction.
Topics: Antidepressive Agents; Aryl Hydrocarbon Hydroxylases; Asian; Benzazepines; Black or African American; Bupropion; Cotinine; Cues; Cytochrome P-450 CYP2A6; Drug Tolerance; Genetic Predisposition to Disease; Harm Reduction; Humans; Menthol; Mixed Function Oxygenases; Neuronal Plasticity; Nicotine; Nicotinic Agonists; Quinoxalines; Receptors, Nicotinic; Reinforcement, Psychology; Smoking; Smoking Cessation; Tobacco Use Disorder; United States; Varenicline; White People | 2008 |
Smoking cessation in pregnancy: why, how, and what next...
Topics: Behavior Therapy; Benzazepines; Bupropion; Counseling; Female; Humans; Nicotine; Pregnancy; Pregnancy Outcome; Quinoxalines; Smoking; Smoking Cessation; Smoking Prevention; Varenicline | 2008 |
[The ABC of smoking cessation].
Topics: Antidepressive Agents, Second-Generation; Benzazepines; Bupropion; Cognitive Behavioral Therapy; Humans; Hypnosis; Motivation; Nicotiana; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Varenicline | 2008 |
Which drug to be used in smoking cessation?
Topics: Benzazepines; Bupropion; Humans; Nicotine; Quinoxalines; Smoking Cessation; Treatment Outcome; Varenicline | 2008 |
Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials.
Topics: Administration, Cutaneous; Administration, Inhalation; Administration, Oral; Benzazepines; Bupropion; Chewing Gum; Female; Follow-Up Studies; Humans; Male; Multivariate Analysis; Nicotine; Nicotinic Agonists; Patient Compliance; Probability; Quebec; Quinoxalines; Risk Assessment; Smoking; Smoking Cessation; Smoking Prevention; Tobacco Use Disorder; Treatment Outcome; Varenicline | 2008 |
Nicotine receptor partial agonists for smoking cessation.
Topics: Alkaloids; Azocines; Benzazepines; Bupropion; Humans; Nicotine; Nicotinic Agonists; Quinolizines; Quinoxalines; Randomized Controlled Trials as Topic; Smoking; Smoking Cessation; Varenicline | 2008 |
The relevance and treatment of cue-induced cravings in tobacco dependence.
Topics: Adaptation, Psychological; Antidepressive Agents, Second-Generation; Benzazepines; Bupropion; Cognitive Behavioral Therapy; Cues; Extinction, Psychological; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Tobacco Use Disorder; Varenicline | 2009 |
Drugs for tobacco dependence.
Topics: Adrenergic alpha-Agonists; Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Tobacco Use Disorder; Varenicline | 2008 |
Multimodal techniques for smoking cessation: a review of their efficacy and utilisation and clinical practice guidelines.
Topics: Benzazepines; Combined Modality Therapy; Complementary Therapies; Drug Therapy, Combination; Humans; Nicotine; Nicotinic Agonists; Practice Guidelines as Topic; Psychotherapy; Quinoxalines; Smoking Cessation; Smoking Prevention; Tobacco Use Disorder; Treatment Outcome; Varenicline | 2008 |
Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics.
Topics: Animals; Behavior, Addictive; Benzazepines; Bupropion; Ganglionic Stimulants; Humans; Nicotine; Nicotinic Agonists; Nonprescription Drugs; Quinoxalines; Smoking; Tobacco Use Disorder; Varenicline | 2009 |
[Modern medical support for smoking cessation].
Topics: Benzazepines; Bupropion; Humans; Nicotine; Practice Patterns, Physicians'; Quinoxalines; Smoking Cessation; Smoking Prevention; Varenicline | 2009 |
[Not smoking, essential for healthy lungs].
Topics: Administration, Cutaneous; Benzazepines; Bupropion; Chewing Gum; Health; Humans; Lung; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Tablets; Varenicline | 2008 |
Smoking cessation in pregnancy.
Topics: Animals; Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Female; Humans; Nicotine; Nicotinic Agonists; Pregnancy; Pregnancy Complications; Quinoxalines; Smoking Cessation; Varenicline | 2008 |
Varenicline for tobacco dependence.
Topics: Benzazepines; Brain; Coronary Artery Disease; Humans; Male; Middle Aged; Motivation; Nicotine; Nicotinic Agonists; Practice Guidelines as Topic; Pulmonary Disease, Chronic Obstructive; Quinoxalines; Receptors, Nicotinic; Smoking Cessation; Tobacco Use Disorder; Varenicline | 2008 |
New findings on nicotine addiction and treatment.
Topics: Animals; Benzazepines; Bupropion; Humans; Mecamylamine; Motivation; Nicotine; Nicotinic Antagonists; Quinoxalines; Reward; Smoking Cessation; Tobacco Use Disorder; Vaccines; Varenicline | 2009 |
Interventions for preventing weight gain after smoking cessation.
Topics: Antidepressive Agents; Benzazepines; Exercise; Female; Humans; Male; Nicotine; Nicotinic Agonists; Piperidines; Pyrazoles; Quinoxalines; Rimonabant; Smoking Cessation; Varenicline; Weight Gain | 2009 |
Smoking in pregnancy and lactation: a review of risks and cessation strategies.
Topics: Adult; Alkaloids; Antidepressive Agents; Azocines; Benzazepines; Breast Feeding; Bromocriptine; Cognitive Behavioral Therapy; Female; Humans; Lactation; Nicotine; Nicotinic Agonists; Pregnancy; Pregnancy Complications; Quinolizines; Quinoxalines; Risk Assessment; Risk Factors; Smoking; Smoking Cessation; Vaccines; Varenicline; Young Adult | 2009 |
[Pharmacotherapy of smoking cessation with application of nicotine and nicotine free drugs].
Topics: Benzazepines; Bupropion; Humans; Nicotine; Quinoxalines; Receptors, Nicotinic; Smoking; Smoking Cessation; Tobacco Use Disorder; Varenicline | 2008 |
A preliminary benefit-risk assessment of varenicline in smoking cessation.
Topics: Antidepressive Agents, Second-Generation; Benzazepines; Bupropion; Humans; Nicotine; Nicotinic Agonists; Product Surveillance, Postmarketing; Quinoxalines; Recurrence; Risk Assessment; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Varenicline | 2009 |
Emerging drugs for the treatment of tobacco dependence.
Topics: Animals; Benzazepines; Clinical Trials as Topic; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Receptors, Nicotinic; Smoking Cessation; Tobacco Use Disorder; Varenicline | 2009 |
Tobacco dependence and withdrawal: science base, challenges and opportunities for pharmacotherapy.
Topics: Animals; Benzazepines; Bupropion; Clinical Trials as Topic; Humans; Nicotine; Quinoxalines; Receptors, Nicotinic; Substance Withdrawal Syndrome; Tobacco Use Cessation; Tobacco Use Disorder; Treatment Outcome; Varenicline | 2009 |
Update on smoking cessation therapies.
Topics: Antidepressive Agents, Second-Generation; Benzazepines; Bupropion; Cost of Illness; Drug Approval; Global Health; Humans; Morbidity; Nicotine; Nicotinic Agonists; Quinoxalines; Safety; Smoking; Smoking Cessation; Smoking Prevention; Treatment Outcome; United States; Varenicline | 2009 |
Smoking and chronic obstructive pulmonary disease (COPD). Parallel epidemics of the 21 century.
Topics: Benzazepines; Bupropion; Combined Modality Therapy; Dopamine Uptake Inhibitors; Humans; Nicotine; Nicotinic Agonists; Pulmonary Disease, Chronic Obstructive; Quinoxalines; Smoking; Smoking Cessation; Varenicline | 2009 |
Pharmacogenetics of smoking cessation therapy.
Topics: Benzazepines; Bupropion; Clonidine; Genome-Wide Association Study; Humans; Nicotine; Nortriptyline; Pharmacogenetics; Quinoxalines; Smoking Cessation; Varenicline | 2010 |
Tobacco use among individuals with intellectual or developmental disabilities: a brief review.
Topics: Adult; Benzazepines; Bupropion; Counseling; Cross-Sectional Studies; Disabled Persons; Health Policy; Humans; Nicotine; Persons with Mental Disabilities; Quinoxalines; Smoking; Smoking Cessation; Tobacco Smoke Pollution; Tobacco Use Disorder; United States; Varenicline | 2009 |
Are nicotine replacement therapy, varenicline or bupropion options for pregnant mothers to quit smoking? Effects on the respiratory system of the offspring.
Topics: Animals; Antioxidants; Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Female; Humans; Maternal-Fetal Exchange; Nicotine; Nicotinic Agonists; Pregnancy; Pregnancy Complications; Quinoxalines; Respiratory System; Smoking; Smoking Cessation; Smoking Prevention; Tobacco Use Disorder; Varenicline | 2009 |
What do we know about the role of pharmacotherapy for smoking cessation before or during pregnancy?
Topics: Animals; Benzazepines; Bupropion; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Nicotine; Pregnancy; Quinoxalines; Randomized Controlled Trials as Topic; Smoking; Smoking Cessation; Varenicline | 2009 |
Current approaches to pharmacotherapy for smoking cessation.
Topics: Adolescent; Adult; Animals; Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Female; Humans; Male; Nicotine; Nicotinic Agonists; Pregnancy; Quinoxalines; Smoking Cessation; Smoking Prevention; Tobacco Use Disorder; United States; Varenicline | 2010 |
Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation.
Topics: Benzazepines; Bupropion; Clinical Trials as Topic; Cost-Benefit Analysis; Delayed-Action Preparations; Health Care Costs; Humans; Models, Statistical; Nicotine; Nicotinic Agonists; Prevalence; Quinoxalines; Smoking Cessation; Tobacco Use Disorder; Varenicline | 2010 |
Smoking cessation intervention: an evidence-based approach.
Topics: Antidepressive Agents, Second-Generation; Behavior Therapy; Benzazepines; Bupropion; Directive Counseling; Drug Therapy, Combination; Evidence-Based Medicine; Global Health; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Smoking Prevention; Varenicline | 2010 |
Improving the effectiveness of tobacco use cessation (TUC).
Topics: Antidepressive Agents, Second-Generation; Behavior Therapy; Benzazepines; Bupropion; Chewing Gum; Counseling; Dental Offices; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Referral and Consultation; Smoking; Tobacco Use Cessation; Varenicline | 2010 |
[Pharmacological profile and clinical findings on varenicline tartrate (Champix tablets)].
Topics: Animals; Benzazepines; Clinical Trials, Phase III as Topic; Corpus Striatum; Dopamine; Humans; Nicotine; Nicotinic Agonists; Nucleus Accumbens; Quinoxalines; Receptors, Nicotinic; Smoking Cessation; Tobacco Use Disorder; Varenicline | 2010 |
Smoking cessation-recent advances.
Topics: Australia; Benzazepines; Bupropion; Cardiovascular Diseases; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Humans; Immunotherapy, Active; Nicotine; Nicotinic Agonists; Quinoxalines; Randomized Controlled Trials as Topic; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Transdermal Patch; Treatment Outcome; United Kingdom; United States; Varenicline | 2010 |
Comparison of available treatments for tobacco addiction.
Topics: Behavior Therapy; Benzazepines; Bupropion; Humans; Nicotine; Nortriptyline; Quinoxalines; Smoking Cessation; Tobacco Use Disorder; Treatment Outcome; Varenicline | 2010 |
[Preventive relapse treatment for tobacco cessation - is it worthwhile?].
Topics: Antidepressive Agents; Behavior Therapy; Benzazepines; Bupropion; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Randomized Controlled Trials as Topic; Secondary Prevention; Smoking Cessation; Treatment Outcome; Varenicline | 2010 |
[Pharmacotherapies for nicotine dependence: review of scientific evidence. Spanish Society of Smoking Specialists: recommendations about election and individualization].
Topics: Benzazepines; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Tobacco Use Disorder; Varenicline | 2011 |
A brief review of pharmacotherapeutic treatment options in smoking cessation: bupropion versus varenicline.
Topics: Antidepressive Agents, Second-Generation; Behavior Therapy; Benzazepines; Bupropion; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Risk Factors; Smoking Cessation; Smoking Prevention; Substance-Related Disorders; Varenicline | 2010 |
Impact of genetic variability in nicotinic acetylcholine receptors on nicotine addiction and smoking cessation treatment.
Topics: Benzazepines; Bupropion; Genetic Variation; Humans; Nicotine; Protein Subunits; Quinoxalines; Receptors, Nicotinic; Smoking Cessation; Tobacco Use Disorder; Varenicline | 2011 |
Adverse effects and tolerability of medications for the treatment of tobacco use and dependence.
Topics: Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Tobacco Use Disorder; Varenicline | 2010 |
Nicotine receptor partial agonists for smoking cessation.
Topics: Alkaloids; Azocines; Benzazepines; Bupropion; Humans; Nicotine; Nicotinic Agonists; Quinolizines; Quinoxalines; Randomized Controlled Trials as Topic; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Varenicline | 2010 |
Interventions for smokeless tobacco use cessation.
Topics: Benzazepines; Bupropion; Chewing Gum; Counseling; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Randomized Controlled Trials as Topic; Tobacco Use Cessation; Tobacco, Smokeless; Varenicline | 2011 |
Nicotine receptor partial agonists for smoking cessation.
Topics: Alkaloids; Azocines; Benzazepines; Bupropion; Humans; Nicotine; Nicotinic Agonists; Quinolizines; Quinoxalines; Randomized Controlled Trials as Topic; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Varenicline | 2011 |
Nicotine dependence: health consequences, smoking cessation therapies, and pharmacotherapy.
Topics: Administration, Cutaneous; Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Heart Diseases; Humans; Neoplasms; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Smoking Prevention; Substance-Related Disorders; Varenicline | 2011 |
Pharmacotherapy for smoking cessation: present and future.
Topics: Adolescent; Animals; Benzazepines; Bupropion; Delayed-Action Preparations; Female; Humans; Nicotine; Nicotinic Agonists; Pregnancy; Quinoxalines; Smoking Cessation; Smoking Prevention; Tobacco Use Disorder; Varenicline | 2011 |
Varenicline for tobacco dependence: panacea or plight?
Topics: Animals; Benzazepines; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Tobacco Use Cessation; Tobacco Use Disorder; Tobacco, Smokeless; Varenicline | 2011 |
Clinical practice. Treating smokers in the health care setting.
Topics: Benzazepines; Bupropion; Cholinergic Agents; Counseling; Dopamine Uptake Inhibitors; Evidence-Based Medicine; Female; Humans; Middle Aged; Motivation; Nicotine; Patient Compliance; Physician-Patient Relations; Practice Guidelines as Topic; Quinoxalines; Smoking; Smoking Cessation; United States; Varenicline | 2011 |
Efficacy and tolerability of pharmacotherapies to aid smoking cessation in adolescents.
Topics: Adolescent; Benzazepines; Bupropion; Clinical Trials as Topic; Dopamine Uptake Inhibitors; Humans; Nicotine; Nicotinic Agonists; Patient Compliance; Prescription Drugs; Quinoxalines; Randomized Controlled Trials as Topic; Safety; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Cessation Devices; Treatment Outcome; Varenicline | 2012 |
Interventions for preventing weight gain after smoking cessation.
Topics: Antidepressive Agents; Benzazepines; Exercise; Female; Humans; Male; Nicotine; Nicotinic Agonists; Piperidines; Pyrazoles; Quinoxalines; Randomized Controlled Trials as Topic; Smoking Cessation; Weight Gain | 2012 |
[Smoking cessation in medical practice--new possibilities?].
Topics: Benzazepines; Bupropion; Complementary Therapies; Drugs, Investigational; General Practitioners; Humans; Nicotine; Nicotinic Agonists; Professional Practice; Quinoxalines; Smoking; Smoking Cessation; Tobacco Use Cessation Devices; Varenicline | 2012 |
Nicotine receptor partial agonists for smoking cessation.
Topics: Alkaloids; Azepines; Azocines; Benzazepines; Bupropion; Counseling; Heterocyclic Compounds, 4 or More Rings; Humans; Nicotine; Nicotinic Agonists; Quinolizines; Quinoxalines; Randomized Controlled Trials as Topic; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Varenicline | 2012 |
The pharmacist "toolbox" for smoking cessation: a review of methods, medicines, and novel means to help patients along the path of smoking reduction to smoking cessation.
Topics: Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Education, Pharmacy, Continuing; Humans; Nicotine; Nicotinic Agonists; Patient Acceptance of Health Care; Pharmacists; Quinoxalines; Smoking; Smoking Cessation; Smoking Prevention; Tobacco Use Cessation Devices; Varenicline | 2012 |
[Drugs used to treat nicotine addiction].
Topics: Adult; Age Distribution; Alkaloids; Azocines; Benzazepines; Bupropion; Causality; Comorbidity; Female; Humans; Male; Middle Aged; Nicotine; Nicotinic Agonists; Poland; Quinolizines; Quinoxalines; Sex Distribution; Smoking; Smoking Cessation; Smoking Prevention; Tobacco Use Disorder; Varenicline; Young Adult | 2012 |
Interventions for smoking cessation and reduction in individuals with schizophrenia.
Topics: Adult; Antidepressive Agents, Second-Generation; Benzazepines; Bupropion; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Randomized Controlled Trials as Topic; Reinforcement, Psychology; Schizophrenia; Schizophrenic Psychology; Smoking Cessation; Smoking Prevention; Tobacco Use Cessation Devices; Varenicline | 2013 |
Smoking cessation and COPD.
Topics: Benzazepines; Bupropion; Counseling; Humans; Nicotine; Nicotinic Agonists; Prevalence; Pulmonary Disease, Chronic Obstructive; Quinoxalines; Risk Factors; Risk Reduction Behavior; Smoking; Smoking Cessation; Smoking Prevention; Tobacco Use Cessation Devices; Tobacco Use Disorder; Treatment Outcome; Varenicline | 2013 |
Smoking cessation treatment for COPD smokers: the role of pharmacological interventions.
Topics: Benzazepines; Bupropion; Humans; Nicotine; Pulmonary Disease, Chronic Obstructive; Quinoxalines; Smoking Cessation; Tobacco Use Cessation Devices; Varenicline | 2013 |
Relapse prevention interventions for smoking cessation.
Topics: Behavior Therapy; Benzazepines; Chewing Gum; Female; Humans; Male; Nicotine; Nicotinic Agonists; Pregnancy; Quinoxalines; Randomized Controlled Trials as Topic; Secondary Prevention; Smoking Cessation; Smoking Prevention; Varenicline | 2013 |
[Nicotine and neurologic diseases--even a noxious substance may possess beneficial properties].
Topics: Alzheimer Disease; Ataxia; Benzazepines; Cognitive Dysfunction; Epilepsy, Frontal Lobe; Humans; Mutation; Nicotine; Nicotinic Agonists; Parkinson Disease; Quinoxalines; Receptors, Nicotinic; Tobacco Use Cessation Devices; Varenicline | 2013 |
Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis.
Topics: Adult; Benzazepines; Bupropion; Cardiovascular Diseases; Dopamine Uptake Inhibitors; Female; Humans; Male; Nicotine; Nicotinic Agonists; Quinoxalines; Risk Factors; Smoking; Smoking Cessation; Varenicline | 2014 |
Pharmacological intervention of nicotine dependence.
Topics: Benzazepines; Bupropion; Humans; Nicotine; Quinoxalines; Tobacco Use Cessation Devices; Tobacco Use Disorder; Varenicline | 2013 |
Smoking cessation.
Topics: Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Humans; Nicotine; Nicotinic Agonists; Pulmonary Disease, Chronic Obstructive; Quinoxalines; Smoking; Smoking Cessation; Tobacco Use Cessation Devices; Varenicline | 2014 |
Emerging drugs for the treatment of tobacco dependence: 2014 update.
Topics: Atomoxetine Hydrochloride; Benzazepines; Bupropion; Clinical Trials as Topic; Clonidine; Humans; Mecamylamine; Nicotine; Nortriptyline; Propylamines; Quinoxalines; Tobacco Use Cessation Devices; Tobacco Use Disorder; Varenicline | 2014 |
Interventions for preoperative smoking cessation.
Topics: Benzazepines; Humans; Nicotine; Nicotinic Agonists; Postoperative Complications; Preoperative Care; Quinoxalines; Randomized Controlled Trials as Topic; Smoking; Smoking Cessation; Tobacco Use Cessation Devices; Varenicline | 2014 |
Effect of Smoking Reduction Therapy on Smoking Cessation for Smokers without an Intention to Quit: An Updated Systematic Review and Meta-Analysis of Randomized Controlled.
Topics: Adult; Aged; Benzazepines; Bupropion; Female; Humans; Intention; Male; Middle Aged; Nicotine; Nicotinic Agonists; Quinoxalines; Randomized Controlled Trials as Topic; Smoking; Smoking Cessation; Varenicline | 2015 |
Interventions for smokeless tobacco use cessation.
Topics: Benzazepines; Bupropion; Chewing Gum; Counseling; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Randomized Controlled Trials as Topic; Tobacco Use Cessation; Tobacco, Smokeless; Varenicline | 2015 |
[Smoking, alcohol and diabetes (Update 2019)].
Topics: Alcohol Drinking; Benzazepines; Bupropion; Diabetes Mellitus; Humans; Nicotine; Practice Guidelines as Topic; Quinoxalines; Smoking; Smoking Cessation; Tobacco Use Cessation Devices; Varenicline | 2019 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea | 2022 |
Pharmacological strategies for smoking cessation in patients with chronic obstructive pulmonary disease: a pragmatic review.
Topics: Benzazepines; Bupropion; Humans; Nicotine; Pulmonary Disease, Chronic Obstructive; Quinoxalines; Smoking Cessation; Tobacco Use Cessation Devices; Varenicline | 2021 |
27 trial(s) available for nicotine and quinoxalines
| Article | Year |
|---|---|
Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers.
Topics: Administration, Oral; Adolescent; Adult; Area Under Curve; Benzazepines; Cotinine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Half-Life; Headache; Humans; Hypotension, Orthostatic; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Nicotine; Patient Dropouts; Quinoxalines; Receptors, Nicotinic; Smoking; Smoking Cessation; Smoking Prevention; Tablets; Varenicline; Vomiting | 2006 |
Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Benzazepines; Female; Humans; Male; Middle Aged; Nicotine; Nicotinic Agonists; Patient Compliance; Quinoxalines; Reinforcement, Psychology; Smoking Cessation; Smoking Prevention; Substance Withdrawal Syndrome; Treatment Outcome; Varenicline | 2008 |
Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzazepines; Carbon Dioxide; Cognition; Dose-Response Relationship, Drug; Humans; Male; Middle Aged; Neuropsychological Tests; Nicotine; Prospective Studies; Psychiatric Status Rating Scales; Psychotic Disorders; Quinoxalines; Schizophrenia; Schizophrenic Psychology; Smoking; Time Factors; Varenicline | 2009 |
Varenicline attenuates some of the subjective and physiological effects of intravenous nicotine in humans.
Topics: Adult; Affect; Benzazepines; Blood Pressure; Cognition Disorders; Cotinine; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heart Rate; Humans; Injections, Intravenous; Male; Middle Aged; Neuropsychological Tests; Nicotine; Nicotinic Agonists; Quinoxalines; Severity of Illness Index; Smoking Cessation; Tobacco Use Disorder; Treatment Outcome; Varenicline | 2009 |
A randomized controlled open comparative trial of varenicline vs nicotine patch in adult smokers: efficacy, safety and withdrawal symptoms (the VN-SEESAW study).
Topics: Administration, Cutaneous; Adult; Benzazepines; Emotions; Endpoint Determination; Female; Humans; Incidence; Male; Middle Aged; Nicotine; Nicotinic Agonists; Quinoxalines; Risk Factors; Smoking; Smoking Cessation; Stress, Psychological; Substance Withdrawal Syndrome; Treatment Outcome; Varenicline | 2010 |
Mouse model predicts effects of smoking and varenicline on event-related potentials in humans.
Topics: Adult; Animals; Benzazepines; Cross-Over Studies; Evoked Potentials; Female; Humans; Male; Mice; Mice, Inbred C57BL; Nicotine; Placebo Effect; Quinoxalines; Smoking; Varenicline; Young Adult | 2010 |
Cross-validation of a new procedure for early screening of smoking cessation medications in humans.
Topics: Administration, Cutaneous; Adult; Benzazepines; Cross-Over Studies; Data Interpretation, Statistical; Double-Blind Method; Drug Evaluation, Preclinical; Female; Humans; Male; Motivation; Nicotine; Nicotinic Agonists; Quinoxalines; Reproducibility of Results; Research Design; Smoking; Smoking Cessation; Surveys and Questionnaires; Varenicline | 2010 |
Brain activity and emotional processing in smokers treated with varenicline.
Topics: Adolescent; Adult; Affect; Aged; Amygdala; Analysis of Variance; Benzazepines; Brain; Cross-Over Studies; Double-Blind Method; Emotions; Facial Expression; Female; Functional Neuroimaging; Humans; Linear Models; Magnetic Resonance Imaging; Male; Middle Aged; Nicotine; Nicotinic Agonists; Oxygen; Photic Stimulation; Placebos; Quinoxalines; Reaction Time; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Treatment Outcome; Varenicline; Young Adult | 2013 |
Safety of varenicline among smokers enrolled in the lung HIV study.
Topics: Adult; Benzazepines; Female; HIV Infections; Humans; Male; Middle Aged; Nicotine; Prospective Studies; Quinoxalines; Smoking Cessation; Treatment Outcome; Varenicline | 2013 |
Effects of 21 days of varenicline versus placebo on smoking behaviors and urges among non-treatment seeking smokers.
Topics: Adult; alpha7 Nicotinic Acetylcholine Receptor; Behavior, Addictive; Benzazepines; Biomarkers; Cotinine; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Nausea; Nicotine; Nicotinic Agonists; Patient Acceptance of Health Care; Pennsylvania; Quinoxalines; Receptors, Nicotinic; Smoking Cessation; Substance Withdrawal Syndrome; Time Factors; Varenicline; Young Adult | 2012 |
Varenicline to stop long-term nicotine replacement use: a double-blind, randomized, placebo-controlled trial.
Topics: Benzazepines; Body Weight; Double-Blind Method; Female; Humans; Male; Middle Aged; Nicotine; Nicotinic Antagonists; Placebos; Quinoxalines; Smoking Cessation; Substance Withdrawal Syndrome; Surveys and Questionnaires; Varenicline | 2013 |
Smoking quit success genotype score predicts quit success and distinct patterns of developmental involvement with common addictive substances.
Topics: Adolescent; Benzazepines; Bupropion; Case-Control Studies; Cohort Studies; Dose-Response Relationship, Drug; Female; Genotype; Humans; Male; Nicotine; Outcome Assessment, Health Care; Polymorphism, Single Nucleotide; Quinoxalines; Reproducibility of Results; Risk Factors; Smoking Cessation; Substance-Related Disorders; Tobacco Use Cessation Devices; Tobacco Use Disorder; Varenicline; Young Adult | 2014 |
Nicotinic acetylcholine receptor variation and response to smoking cessation therapies.
Topics: Adult; Antidepressive Agents, Second-Generation; Behavior Therapy; Benzazepines; Bupropion; Female; Genotype; Humans; Male; Middle Aged; Nicotine; Nicotinic Agonists; Polymorphism, Single Nucleotide; Quinoxalines; Receptors, Nicotinic; Recurrence; Smoking; Smoking Cessation; Varenicline | 2013 |
Down-regulation of amygdala and insula functional circuits by varenicline and nicotine in abstinent cigarette smokers.
Topics: Adolescent; Adult; Amygdala; Benzazepines; Brain Mapping; Cerebral Cortex; Double-Blind Method; Down-Regulation; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Nicotine; Nicotinic Agonists; Quinoxalines; Rest; Smoking Cessation; Varenicline; Young Adult | 2013 |
Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal.
Topics: Adolescent; Adult; Affect; Aged; Benzazepines; Bupropion; Combined Modality Therapy; Counseling; Delayed-Action Preparations; Depression; Female; Humans; Male; Middle Aged; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Treatment Outcome; Varenicline; Young Adult | 2013 |
Effect of varenicline on individual nicotine withdrawal symptoms: a combined analysis of eight randomized, placebo-controlled trials.
Topics: Adult; Aged; Benzazepines; Double-Blind Method; Female; Humans; Male; Middle Aged; Nicotine; Nicotinic Agonists; Quinoxalines; Sleep Wake Disorders; Smoking Cessation; Smoking Prevention; Substance Withdrawal Syndrome; Varenicline | 2013 |
Commitment contracts and team incentives: a randomized controlled trial for smoking cessation in Thailand.
Topics: Adult; Aged; Benzazepines; Contracts; Cost-Benefit Analysis; Counseling; Female; Humans; Male; Middle Aged; Motivation; Nicotine; Quinoxalines; Rural Population; Smoking Cessation; Thailand; Time Factors; Tobacco Use Cessation Devices; Tobacco Use Disorder; Treatment Outcome; Varenicline | 2013 |
A pragmatic, randomized, controlled study evaluating the impact of access to smoking cessation pharmacotherapy coverage on the proportion of successful quitters in a Canadian population of smokers motivated to quit (ACCESSATION).
Topics: Benzazepines; Bupropion; Canada; Female; Health Services Accessibility; Humans; Insurance, Health; Male; Middle Aged; Motivation; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Tobacco Use Cessation Devices; Tobacco Use Disorder; Treatment Outcome; Varenicline | 2014 |
Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial.
Topics: Adult; Benzazepines; Breath Tests; Carbon Monoxide; Cholinergic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Nicotine; Quinoxalines; Smoking Cessation; Tobacco Use Cessation Devices; Tobacco Use Disorder; Treatment Outcome; Varenicline | 2014 |
Pharmacokinetic-pharmacodynamic modeling of the effect of varenicline on nicotine craving in adult smokers.
Topics: Adolescent; Adult; Benzazepines; Craving; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Surveys and Questionnaires; Varenicline | 2015 |
Combining varenicline and nicotine patches: a randomized controlled trial study in smoking cessation.
Topics: Administration, Cutaneous; Adolescent; Adult; Benzazepines; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Tobacco Use Cessation Devices; Tobacco Use Disorder; Treatment Outcome; Varenicline | 2014 |
[Smoking cessation: varenicline/nicotine patch combination more effective than varenicline alone].
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Benzazepines; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Nicotine; Quinoxalines; Smoking Cessation; Treatment Outcome; Varenicline; Young Adult | 2014 |
Impact of cigarette smoking cessation on high-density lipoprotein functionality.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Administration, Cutaneous; Adult; Apolipoprotein A-I; Benzazepines; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholinergic Agonists; Female; Humans; Inflammation; Lipid Peroxidation; Lipids; Lipoproteins, HDL; Macrophages; Male; Malondialdehyde; Middle Aged; Nicotine; Oxidation-Reduction; Quinoxalines; Receptors, Nicotinic; Risk Factors; Smoking; Smoking Cessation; Varenicline | 2014 |
Increasing progesterone levels are associated with smoking abstinence among free-cycling women smokers who receive brief pharmacotherapy.
Topics: Adolescent; Adult; Benzazepines; Estradiol; Female; Humans; Menstrual Cycle; Middle Aged; Nicotine; Nicotinic Agonists; Progesterone; Quinoxalines; Smoking Cessation; Transdermal Patch; Treatment Outcome; Varenicline; Women's Health | 2015 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea | 2022 |
Medication adherence and rate of nicotine metabolism are associated with response to treatment with varenicline among smokers with HIV.
Topics: Adolescent; Benzazepines; HIV Infections; Humans; Medication Adherence; Nicotine; Nicotinic Agonists; Quinoxalines; Smokers; Varenicline | 2021 |
147 other study(ies) available for nicotine and quinoxalines
| Article | Year |
|---|---|
Variable alpha 2-adrenoceptor-mediated inhibition of bronchoconstriction and peptide release upon activation of pulmonary afferents.
Topics: Adrenergic alpha-Agonists; Afferent Pathways; Animals; Bradykinin; Brimonidine Tartrate; Bronchoconstriction; Calcitonin Gene-Related Peptide; Capsaicin; Diterpenes; Electric Stimulation; Guinea Pigs; Imidazoles; In Vitro Techniques; Lung; Neurokinin A; Nicotine; Peptides; Quinoxalines; Vagus Nerve | 1992 |
Tobacco-specific nitrosamines in the saliva of Inuit snuff dippers in the Northwest Territories of Canada.
Topics: Canada; Cell Nucleus; Cotinine; Humans; Inuit; Male; Mouth Mucosa; Nicotiana; Nicotine; Nitrosamines; Plants, Toxic; Precancerous Conditions; Quinoxalines; Saliva; Tobacco Use Disorder; Tobacco, Smokeless | 1987 |
Nicotinic and muscarinic modulations of excitatory synaptic transmission in the rat prefrontal cortex in vitro.
Topics: 2-Amino-5-phosphonovalerate; 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Atropine; Bungarotoxins; Cerebral Cortex; Dimethylphenylpiperazinium Iodide; Electric Stimulation; Evoked Potentials; Hexamethonium; Hexamethonium Compounds; In Vitro Techniques; Male; Mecamylamine; Membrane Potentials; Muscarine; Neurons; Nicotine; Pirenzepine; Pyramidal Tracts; Quinoxalines; Rats; Rats, Sprague-Dawley; Scopolamine; Synaptic Transmission; Tubocurarine | 1993 |
Activation of sensory nerves in guinea-pig isolated basilar artery by nicotine: evidence for inhibition of trigeminal sensory neurotransmission by sumatriptan.
Topics: Animals; Basilar Artery; Brimonidine Tartrate; Calcitonin Gene-Related Peptide; Electric Stimulation; Guinea Pigs; In Vitro Techniques; Male; Nicotine; Peptide Fragments; Potassium Chloride; Quinoxalines; Sumatriptan; Synaptic Transmission; Trigeminal Nerve | 1994 |
Properties of carbachol-induced oscillatory activity in rat hippocampus.
Topics: 2-Amino-5-phosphonovalerate; Animals; Atropine; Bicuculline; Carbachol; Dicyclomine; Evoked Potentials; Excitatory Amino Acid Antagonists; Excitatory Postsynaptic Potentials; GABA Antagonists; GABA-B Receptor Antagonists; Hippocampus; In Vitro Techniques; Kinetics; Male; Microelectrodes; Neurons; Nicotine; Oscillometry; Phosphinic Acids; Pirenzepine; Potassium; Propanolamines; Pyramidal Cells; Quinoxalines; Rats; Rats, Sprague-Dawley; Reaction Time; Receptors, AMPA; Receptors, GABA-B | 1997 |
Nerve-induced release of nitric oxide exerts dual effects on nicotinic transmission within the coeliac ganglion in the rabbit.
Topics: Animals; Arginine; Electric Stimulation; Enzyme Inhibitors; Female; Ganglia; Ganglia, Sympathetic; Male; Neurons; NG-Nitroarginine Methyl Ester; Nicotine; Nitric Oxide; Nitroarginine; Oxadiazoles; Quinoxalines; Rabbits; Splanchnic Nerves; Synapses; Synaptic Transmission; Time Factors | 1998 |
Short-term treatment with transdermal nicotine affects the function of canine saphenous veins.
Topics: Administration, Cutaneous; Adrenergic alpha-Agonists; Animals; Brimonidine Tartrate; Calcimycin; Dogs; Dose-Response Relationship, Drug; Endothelium, Vascular; In Vitro Techniques; Isometric Contraction; Male; Muscle Relaxation; Muscle, Smooth, Vascular; Nicotine; Nitric Oxide; omega-N-Methylarginine; Potassium Chloride; Quinoxalines; Saphenous Vein | 2000 |
Long-term potentiation of excitatory inputs to brain reward areas by nicotine.
Topics: Animals; Dopamine; Dose-Response Relationship, Drug; Electric Stimulation; Excitatory Amino Acid Antagonists; Excitatory Postsynaptic Potentials; gamma-Aminobutyric Acid; In Vitro Techniques; Long-Term Potentiation; Neurons; Nicotine; Nicotinic Agonists; Patch-Clamp Techniques; Presynaptic Terminals; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Synaptic Transmission; Ventral Tegmental Area | 2000 |
Regulation of GABA release by nicotinic acetylcholine receptors in the neonatal rat hippocampus.
Topics: Acetylcholine; Aconitine; alpha7 Nicotinic Acetylcholine Receptor; Animals; Animals, Newborn; Bicuculline; Bridged-Ring Compounds; Dihydro-beta-Erythroidine; Excitatory Amino Acid Antagonists; GABA Antagonists; gamma-Aminobutyric Acid; Glutamic Acid; Hippocampus; Insecticides; Membrane Potentials; Nicotine; Nicotinic Agonists; Organ Culture Techniques; Patch-Clamp Techniques; Pyramidal Cells; Quinoxalines; Rats; Rats, Wistar; Receptors, Nicotinic; Spiro Compounds | 2001 |
Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas.
Topics: Acetylcholinesterase; Action Potentials; Adolescent; Animals; Atropine; Cholinergic Antagonists; Cholinesterase Inhibitors; Dopamine; Electrophysiology; Excitatory Amino Acid Antagonists; gamma-Aminobutyric Acid; Ganglionic Stimulants; Glutamic Acid; Humans; In Vitro Techniques; Insecticides; Mice; Muscarinic Antagonists; Neurons; Nicotine; Organothiophosphorus Compounds; Patch-Clamp Techniques; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Reward; Smoking; Synaptic Transmission; Ventral Tegmental Area | 2002 |
Mechanism of nicotine-evoked release of 3H-noradrenaline in human cerebral cortex slices.
Topics: Adolescent; Adult; Arginine; Calcium; Calcium Channel Blockers; Cerebral Cortex; Dihydro-beta-Erythroidine; Dizocilpine Maleate; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fluoxetine; Ganglionic Stimulants; Guanylate Cyclase; Humans; In Vitro Techniques; Indazoles; Male; Mecamylamine; Methylene Blue; Neuroprotective Agents; NG-Nitroarginine Methyl Ester; Nicotine; Nicotinic Antagonists; Nitrendipine; Nitric Oxide Synthase; Norepinephrine; omega-Conotoxin GVIA; Oxadiazoles; Purinones; Quinoxalines; Tetrodotoxin; Tritium; Tubocurarine | 2002 |
Neurotransmitter release and its presynaptic modulation in the rat hippocampus after selective damage to cholinergic or/and serotonergic afferents.
Topics: 5,7-Dihydroxytryptamine; Acetylcholine; Adrenergic alpha-Agonists; Animals; Antibodies, Monoclonal; Biogenic Monoamines; Brimonidine Tartrate; Choline O-Acetyltransferase; Cholinergic Agents; Cholinergic Fibers; Electric Stimulation; Hippocampus; Immunotoxins; Male; N-Glycosyl Hydrolases; Neurons, Afferent; Neurotoxins; Nicotine; Nicotinic Agonists; Norepinephrine; Organ Culture Techniques; Pyridines; Pyrroles; Quinoxalines; Rats; Rats, Long-Evans; Ribosome Inactivating Proteins, Type 1; Saporins; Serotonin; Serotonin Agents; Serotonin Receptor Agonists | 2003 |
Group II metabotropic and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate glutamate receptors regulate the deficit in brain reward function associated with nicotine withdrawal in rats.
Topics: Animals; Bridged Bicyclo Compounds; Dizocilpine Maleate; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Male; Nicotine; Pyridines; Quinoxalines; Rats; Rats, Wistar; Receptors, AMPA; Receptors, Glutamate; Receptors, Kainic Acid; Receptors, Metabotropic Glutamate; Receptors, N-Methyl-D-Aspartate; Reward; Substance Withdrawal Syndrome; Ventral Tegmental Area | 2003 |
Nicotine-induced dopamine release in the nucleus accumbens is inhibited by the novel AMPA antagonist ZK200775 and the NMDA antagonist CGP39551.
Topics: 2-Amino-5-phosphonovalerate; Animals; Cell Survival; Cells, Cultured; Cerebellum; Dopamine; Male; Microdialysis; Motor Activity; Nicotine; Nucleus Accumbens; Organophosphonates; Quinoxalines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Receptors, Nicotinic; Time Factors | 2004 |
The linoleic acid derivative FR236924 facilitates hippocampal synaptic transmission by enhancing activity of presynaptic alpha7 acetylcholine receptors on the glutamatergic terminals.
Topics: Alkanes; Animals; Bicuculline; Bungarotoxins; Chromatography, High Pressure Liquid; Cyclopropanes; Dose-Response Relationship, Drug; Drug Interactions; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Excitatory Postsynaptic Potentials; GABA Antagonists; Glutamic Acid; Hippocampus; In Vitro Techniques; Indoles; Linoleic Acid; Lysine; Male; Maleimides; Mecamylamine; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Patch-Clamp Techniques; Presynaptic Terminals; Protein Kinase C; Pyramidal Cells; Quinoxalines; Rats; Rats, Wistar; Receptors, Nicotinic; Receptors, Presynaptic; Synaptic Transmission; Valine | 2005 |
Prefrontal cortical modulation of acetylcholine release in posterior parietal cortex.
Topics: Acetylcholine; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Analysis of Variance; Animals; Atropine; Carbachol; Cholinergic Agonists; Cholinergic Fibers; Dose-Response Relationship, Drug; Drug Combinations; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Male; Mecamylamine; Microdialysis; Muscarinic Antagonists; Nicotine; Nicotinic Antagonists; Parietal Lobe; Prefrontal Cortex; Quinoxalines; Rats; Rats, Inbred F344 | 2005 |
[Medication for ending tobacco dependency. Current state].
Topics: Antidepressive Agents, Second-Generation; Benzazepines; Bupropion; Cannabinoid Receptor Antagonists; Humans; Nicotine; Piperidines; Pyrazoles; Quinoxalines; Receptors, Nicotinic; Rimonabant; Smoking Cessation; Time Factors; Tobacco Use Disorder; Varenicline | 2005 |
Nicotine-induced switch in the nicotinic cholinergic mechanisms of facilitation of long-term potentiation induction.
Topics: Acetylcholinesterase; Aconitine; Animals; Animals, Newborn; Antibodies, Monoclonal; Cholinergic Fibers; Denervation; Dihydro-beta-Erythroidine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Electric Stimulation; Excitatory Amino Acid Antagonists; GABA Antagonists; gamma-Aminobutyric Acid; Hippocampus; Immunohistochemistry; Immunotoxins; In Vitro Techniques; Long-Term Potentiation; N-Glycosyl Hydrolases; Neural Inhibition; Neurons; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Patch-Clamp Techniques; Phosphinic Acids; Picrotoxin; Propanolamines; Quinoxalines; Rats; Receptors, Nicotinic; Ribosome Inactivating Proteins, Type 1; Saporins; Valine | 2005 |
Ligands selective for alpha4beta2 but not alpha3beta4 or alpha7 nicotinic receptors generalise to the nicotine discriminative stimulus in the rat.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Appetitive Behavior; Azetidines; Benzazepines; Corpus Striatum; Cystine; Discrimination Learning; Dose-Response Relationship, Drug; Male; Motivation; Nicotine; Nicotinic Agonists; Pyridines; Quinoxalines; Rats; Rats, Inbred Strains; Receptors, Nicotinic; Tobacco Use Disorder; Varenicline | 2007 |
Nicotine withdrawal suppresses nicotinic modulation of long-term potentiation induction in the hippocampal CA1 region.
Topics: Animals; Azetidines; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Electric Stimulation; Excitatory Amino Acid Antagonists; Excitatory Postsynaptic Potentials; Female; GABA Antagonists; Hippocampus; Inhibitory Postsynaptic Potentials; Long-Term Potentiation; Male; Nicotine; Nicotinic Agonists; Picrotoxin; Quinoxalines; Rats; Substance Withdrawal Syndrome; Time Factors; Up-Regulation | 2006 |
Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.
Topics: Animals; Behavior, Animal; Benzazepines; Brain; Cell Line, Transformed; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; In Vitro Techniques; Male; Membrane Potentials; Nicotine; Nicotinic Agonists; Patch-Clamp Techniques; Protein Binding; Quinoxalines; Rats; Rats, Long-Evans; Rats, Sprague-Dawley; Self Administration; Smoking Cessation; Transfection; Varenicline | 2007 |
Varenicline: new drug. Smoking cessation: no better than nicotine.
Topics: Benzazepines; France; Humans; Nicotine; Quinoxalines; Randomized Controlled Trials as Topic; Smoking Cessation; United States | 2006 |
Involvement of the alpha4beta2 nicotinic receptor subtype in nicotine-induced attenuation of delta9-THC cerebellar ataxia: role of cerebellar nitric oxide.
Topics: Animals; Area Under Curve; Cerebellar Ataxia; Cerebellum; Chalcones; Cyclic GMP; Dronabinol; Enzyme Inhibitors; Guanylate Cyclase; Male; Mice; Microinjections; Nicotine; Nicotinic Agonists; Nitric Oxide; Nitroprusside; Oxadiazoles; Postural Balance; Quinoxalines; Receptor, Cannabinoid, CB1; Receptors, Nicotinic; Stereotaxic Techniques | 2007 |
[The path from cigarettes--with support it works better].
Topics: Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Varenicline | 2007 |
Exacerbation of schizophrenia by varenicline.
Topics: Acute Disease; Benzazepines; Cognition Disorders; Comorbidity; Female; Humans; Middle Aged; Nicotine; Quinoxalines; Recurrence; Schizophrenia; Schizophrenic Psychology; Self Medication; Smoking; Smoking Cessation; Varenicline | 2007 |
Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzazepines; Bupropion; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Male; Middle Aged; Models, Theoretical; Netherlands; Nicotine; Nortriptyline; Quality of Life; Quinoxalines; Smoking; Smoking Cessation; Varenicline | 2008 |
Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness.
Topics: Adult; Benzazepines; Cohort Studies; Drug Combinations; Female; Follow-Up Studies; Humans; London; Male; Mental Disorders; Middle Aged; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Disorder; Treatment Outcome; Varenicline | 2008 |
[New drugs; varenicline].
Topics: Benzazepines; Humans; Nausea; Nicotine; Nicotinic Agonists; Quinoxalines; Receptors, Nicotinic; Smoking Cessation; Varenicline | 2007 |
The truth about smoking cessation.
Topics: Antidepressive Agents, Second-Generation; Benzazepines; Bupropion; Counseling; Humans; Middle Aged; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Varenicline | 2007 |
Breaking away from a narrow prescribing protocol for medicinal nicotine.
Topics: Administration, Cutaneous; Adult; Benzazepines; Humans; Nicotine; Nicotinic Agonists; Patient Acceptance of Health Care; Quinoxalines; Smoking Cessation; Substance Withdrawal Syndrome; Varenicline | 2008 |
Stat bite: Medicaid coverage of tobacco-dependence treatments.
Topics: Administration, Cutaneous; Administration, Intranasal; Administration, Oral; Antidepressive Agents, Second-Generation; Benzazepines; Bupropion; Counseling; Dopamine Uptake Inhibitors; Female; Humans; Insurance Coverage; Male; Medicaid; Nicotine; Nicotinic Agonists; Pregnancy; Pregnancy Complications; Quinoxalines; Tobacco Use Disorder; United States; Varenicline | 2008 |
Smoking cessation 2008.
Topics: Benzazepines; Cannabinoid Receptor Antagonists; Drug Prescriptions; Humans; Marketing of Health Services; Nicotine; Nicotinic Agonists; Piperidines; Pyrazoles; Quinoxalines; Rimonabant; Smoking; Smoking Cessation; Smoking Prevention; Vaccines; Varenicline | 2008 |
Glutamatergic contributions to nicotinic acetylcholine receptor agonist-evoked cholinergic transients in the prefrontal cortex.
Topics: Acetylcholine; Analysis of Variance; Animals; Choline; Dihydro-beta-Erythroidine; Dose-Response Relationship, Drug; Electrochemistry; Evoked Potentials; Excitatory Amino Acid Antagonists; Glutamic Acid; In Vitro Techniques; Male; Mecamylamine; Neostigmine; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Prefrontal Cortex; Pyridines; Pyrrolidines; Quinoxalines; Rats; Sodium Channel Blockers; Tetrodotoxin; Valine | 2008 |
Varenicline: myocardial infarction: nicotine replacement is a better option.
Topics: Benzazepines; Europe; Humans; Myocardial Infarction; Nicotine; Quinoxalines; Smoking Cessation | 2008 |
NMDA receptors regulate nicotine-enhanced brain reward function and intravenous nicotine self-administration: role of the ventral tegmental area and central nucleus of the amygdala.
Topics: Amygdala; Animals; Blotting, Western; Catheterization; Electrodes, Implanted; Excitatory Postsynaptic Potentials; Feeding Behavior; Isoquinolines; Male; Nicotine; Nucleus Accumbens; Patch-Clamp Techniques; Prefrontal Cortex; Quinoxalines; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Reward; Self Administration; Ventral Tegmental Area | 2009 |
Pharmacological effects of nicotine on norepinephrine metabolism in rat brown adipose tissue: relevance to nicotinic therapies for smoking cessation.
Topics: Adipose Tissue, Brown; Animals; Benzazepines; Dose-Response Relationship, Drug; Female; Lipoma; Male; Mediastinal Neoplasms; Nicotine; Nicotinic Agonists; Norepinephrine; Quinoxalines; Rats; Rats, Sprague-Dawley; Sex Factors; Smoking Cessation; Varenicline | 2008 |
Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers.
Topics: Adolescent; Adult; Benzazepines; Bupropion; Costs and Cost Analysis; Drug Costs; Female; Humans; Male; Markov Chains; Middle Aged; Models, Statistical; Nicotine; Quinoxalines; Smoking; Smoking Cessation; United States; Varenicline | 2008 |
Varenicline: depression and suicide. Nicotine is a safer option.
Topics: Benzazepines; Depression; Humans; Nicotine; Quinoxalines; Smoking Cessation; Suicide | 2008 |
Pre-cessation varenicline treatment vs post-cessation NRT: an uneven playing field.
Topics: Benzazepines; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Smoking Prevention; Varenicline | 2008 |
Clinically significant outcomes in smoking cessation.
Topics: Benzazepines; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Smoking Prevention; Treatment Outcome; Varenicline | 2008 |
Effect of varenicline on the acute and repeated locomotor responses to nicotine in rats.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Benzazepines; Drug Administration Schedule; Male; Motor Activity; Nicotine; Quinoxalines; Rats; Rats, Wistar; Receptors, Nicotinic; Varenicline | 2008 |
Differential effects of 5-HT2C receptor activation by WAY 161503 on nicotine-induced place conditioning and locomotor activity in rats.
Topics: Aminopyridines; Amphetamine; Animals; Conditioning, Operant; Dopamine Agents; Dose-Response Relationship, Drug; Indoles; Injections, Intraperitoneal; Injections, Subcutaneous; Male; Motor Activity; Nicotine; Nicotinic Agonists; Pyrazines; Quinoxalines; Rats; Rats, Sprague-Dawley; Reinforcement, Psychology; Reward; Serotonin 5-HT2 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists | 2009 |
Effects of the nicotinic receptor partial agonists varenicline and cytisine on the discriminative stimulus effects of nicotine in rats.
Topics: Alkaloids; Animals; Azocines; Benzazepines; Conditioning, Operant; Data Interpretation, Statistical; Discrimination, Psychological; Dose-Response Relationship, Drug; Generalization, Stimulus; Male; Nicotine; Nicotinic Agonists; Quinolizines; Quinoxalines; Rats; Rats, Long-Evans; Receptors, Nicotinic; Varenicline | 2009 |
An algorithm for tailoring pharmacotherapy for smoking cessation: results from a Delphi panel of international experts.
Topics: Algorithms; Behavior Therapy; Benzazepines; Bupropion; Combined Modality Therapy; Consensus; Decision Support Techniques; Delphi Technique; Humans; Nicotine; Nicotinic Agonists; Practice Patterns, Physicians'; Quinoxalines; Smoking Cessation; Varenicline | 2009 |
Targeting reward-relevant nicotinic receptors in the discovery of novel pharmacotherapeutic agents to treat tobacco dependence.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Benzazepines; Brain; Bupropion; Dopamine; Dose-Response Relationship, Drug; Drugs, Investigational; Male; Neurons; Nicotine; Nicotinic Antagonists; Picolines; Quaternary Ammonium Compounds; Quinoxalines; Rats; Rats, Inbred F344; Rats, Sprague-Dawley; Receptors, Nicotinic; Reward; Smoking Cessation; Structure-Activity Relationship; Tobacco Use Disorder; Varenicline; Ventral Tegmental Area | 2009 |
[Drug treatment for smoking and marijuana abuse].
Topics: Antidepressive Agents, Second-Generation; Benzazepines; Humans; Marijuana Abuse; Nicotine; Nicotinic Agonists; Quinoxalines; Receptors, Nicotinic; Smoking Cessation; Varenicline | 2008 |
The smoking cessation medication varenicline attenuates alcohol and nicotine interactions in the rat mesolimbic dopamine system.
Topics: Animals; Benzazepines; Central Nervous System Depressants; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Ethanol; Limbic System; Male; Microdialysis; Nicotine; Nucleus Accumbens; Quinoxalines; Rats; Rats, Wistar; Smoking Cessation; Varenicline | 2009 |
Do implementation issues influence the effectiveness of medications? The case of nicotine replacement therapy and bupropion in UK Stop Smoking Services.
Topics: Administration, Cutaneous; Adult; Benzazepines; Bupropion; Cohort Studies; Community Health Services; Female; Follow-Up Studies; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Nicotine; Nicotinic Agonists; Patient Participation; Probability; Program Evaluation; Quinoxalines; Randomized Controlled Trials as Topic; Risk Factors; Smoking; Smoking Cessation; Smoking Prevention; Treatment Outcome; United Kingdom; Varenicline; Young Adult | 2009 |
Properties of distinct ventral tegmental area synapses activated via pedunculopontine or ventral tegmental area stimulation in vitro.
Topics: Aconitine; Afferent Pathways; alpha7 Nicotinic Acetylcholine Receptor; Animals; Bicuculline; Dihydro-beta-Erythroidine; Electric Stimulation; Excitatory Amino Acid Antagonists; GABA Antagonists; In Vitro Techniques; Nicotine; Nicotinic Antagonists; Patch-Clamp Techniques; Pedunculopontine Tegmental Nucleus; Picrotoxin; Quinoxalines; Rats; Rats, Sprague-Dawley; Reaction Time; Receptors, Nicotinic; Strontium; Synapses; Synaptic Transmission; Ventral Tegmental Area | 2009 |
A reader responds to "Seven pharmacotherapies do promote smoking abstinence at 6 and 12 months".
Topics: Administration, Cutaneous; Administration, Inhalation; Administration, Oral; Benzazepines; Bupropion; Chewing Gum; Female; Follow-Up Studies; Humans; Male; Multivariate Analysis; Nicotine; Nicotinic Agonists; Patient Compliance; Probability; Quebec; Quinoxalines; Risk Assessment; Smoking; Smoking Cessation; Smoking Prevention; Tobacco Use Disorder; Treatment Outcome; Varenicline | 2008 |
Combination treatment with varenicline and nicotine replacement therapy.
Topics: Adult; Aged; Benzazepines; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Nicotine; Nicotinic Agonists; Outcome Assessment, Health Care; Quinoxalines; Smoking Cessation; Varenicline | 2009 |
Varenicline attenuates nicotine-enhanced brain-stimulation reward by activation of alpha4beta2 nicotinic receptors in rats.
Topics: Animals; Benzazepines; Conditioning, Operant; Dose-Response Relationship, Drug; Drug Interactions; Electric Stimulation; Male; Medial Forebrain Bundle; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Quinoxalines; Rats; Rats, Long-Evans; Receptors, Nicotinic; Reward; Varenicline | 2009 |
Treatment of comorbid tobacco use in people with serious mental illness.
Topics: Adult; Benzazepines; Bupropion; Comorbidity; Counseling; Dopamine Uptake Inhibitors; Female; Follow-Up Studies; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Schizophrenia, Paranoid; Smoking; Smoking Cessation; Varenicline | 2009 |
Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation--results from four European countries.
Topics: Adolescent; Adult; Aged; Benzazepines; Cost-Benefit Analysis; Europe; Female; Heart Diseases; Humans; Incidence; Lung Neoplasms; Male; Markov Chains; Middle Aged; Models, Statistical; Nicotine; Nicotinic Agonists; Pulmonary Disease, Chronic Obstructive; Quality-Adjusted Life Years; Quinoxalines; Smoking; Smoking Cessation; Stroke; Varenicline; Young Adult | 2009 |
[Current and future medical drugs for smoking cessation].
Topics: Adrenergic alpha-Agonists; Antidepressive Agents; Behavior Therapy; Benzazepines; Bupropion; Cannabinoid Receptor Antagonists; Clinical Trials as Topic; Clonidine; Combined Modality Therapy; Counseling; Humans; Nicotine; Nicotinic Agonists; Nortriptyline; Piperidines; Pyrazoles; Quinoxalines; Rimonabant; Smoking Cessation; Tobacco Use Disorder; Vaccines; Varenicline | 2009 |
Cost-effectiveness of varenicline for smoking cessation.
Topics: Benzazepines; Bupropion; Clinical Trials as Topic; Cost Savings; Cost-Benefit Analysis; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Smoking Prevention; Varenicline | 2009 |
Varenicline: a British review. Unfavorable risk-benefit balance.
Topics: Benzazepines; France; Humans; Nicotine; Quinoxalines; Receptors, Nicotinic; Smoking Cessation; Tobacco Use Disorder; United Kingdom | 2008 |
Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis.
Topics: Adolescent; Adult; Age Factors; Aged; Antidepressive Agents, Second-Generation; Belgium; Benzazepines; Bupropion; Computer Simulation; Cost-Benefit Analysis; Counseling; Female; Humans; Male; Markov Chains; Middle Aged; Models, Statistical; Nicotine; Nicotinic Agonists; Quinoxalines; Recurrence; Smoking; Smoking Cessation; Treatment Outcome; Varenicline; Young Adult | 2009 |
Smoking cessation: how to advise the patient.
Topics: Ambulatory Care; Behavior Therapy; Benzazepines; Bupropion; Counseling; Dopamine Uptake Inhibitors; Humans; Motivation; Nicotine; Nicotinic Agonists; Patient Education as Topic; Physician-Patient Relations; Quinoxalines; Secondary Prevention; Smoking Cessation; Smoking Prevention; Varenicline | 2009 |
Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzazepines; Bupropion; Cohort Studies; Dopamine Uptake Inhibitors; Family Practice; Female; Ganglionic Stimulants; Humans; Male; Middle Aged; Nicotine; Quinoxalines; Smoking Cessation; Suicide; Varenicline; Young Adult | 2009 |
Effect of the alpha4beta2* nicotinic acetylcholine receptor partial agonist varenicline on dopamine release in beta2 knock-out mice with selective re-expression of the beta2 subunit in the ventral tegmental area.
Topics: Animals; Benzazepines; Dopamine; Extracellular Space; Genetic Vectors; Green Fluorescent Proteins; Lentivirus; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Microdialysis; Nicotine; Nicotinic Agonists; Nucleus Accumbens; Quinoxalines; Receptors, Nicotinic; Varenicline | 2010 |
[Drug treatment of tobacco dependence].
Topics: Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Humans; Meta-Analysis as Topic; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Tobacco Use Disorder; Varenicline | 2009 |
The alpha4beta2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in rats.
Topics: Animals; Association Learning; Behavior, Animal; Benzazepines; Conditioning, Operant; Cues; Dose-Response Relationship, Drug; Exploratory Behavior; Food; Male; Models, Animal; Nicotine; Nicotinic Agonists; Quinoxalines; Rats; Receptors, Nicotinic; Recurrence; Reinforcement, Psychology; Self Administration; Tobacco Use Disorder; Varenicline | 2010 |
Activation of presynaptic alpha7 nicotinic receptors evokes an excitatory response in hippocampal CA3 neurones in anaesthetized rats: an in vivo iontophoretic study.
Topics: 2-Amino-5-phosphonovalerate; Aconitine; Animals; Bridged Bicyclo Compounds, Heterocyclic; Bridged-Ring Compounds; D-Aspartic Acid; Glutamic Acid; Hippocampus; Male; N-Methylaspartate; Neurons; Nicotine; Nicotinic Antagonists; Pyridines; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Receptors, Presynaptic; Spiro Compounds | 2010 |
Effects of varenicline and mecamylamine on the acquisition, expression, and reinstatement of nicotine-conditioned place preference by drug priming in rats.
Topics: Animals; Benzazepines; Conditioning, Classical; Dose-Response Relationship, Drug; Male; Mecamylamine; Morphine; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Quinoxalines; Rats; Rats, Wistar; Receptors, Nicotinic; Reward; Tobacco Use Disorder; Varenicline | 2010 |
Extinction with varenicline and nornicotine, but not ABT-418, weakens conditioned responding evoked by the interoceptive stimulus effects of nicotine.
Topics: Animals; Benzazepines; Conditioning, Classical; Discrimination, Psychological; Extinction, Psychological; Generalization, Psychological; Isoxazoles; Ligands; Male; Nicotine; Nicotinic Agonists; Pyrrolidines; Quinoxalines; Rats; Rats, Sprague-Dawley; Varenicline | 2010 |
Varenicline treatment decreases DNMT1 mRNA expression in lymphocytes of schizophrenic patients who are cigarette smokers.
Topics: Benzazepines; Cotinine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Gene Expression; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; RNA, Messenger; Schizophrenia; Smoking Cessation; Varenicline | 2010 |
Characteristics and abstinence outcomes among tobacco quitline enrollees using varenicline or nicotine replacement therapy.
Topics: Adolescent; Adult; Benzazepines; Counseling; Female; Humans; Male; Montana; Nicotine; Nicotinic Agonists; Quinoxalines; Retrospective Studies; Smoking Cessation; Telephone; Tobacco Use Disorder; Treatment Outcome; Varenicline; Young Adult | 2010 |
Nicotinic partial agonists varenicline and sazetidine-A have differential effects on affective behavior.
Topics: Animals; Anxiety; Azetidines; Behavior, Animal; Benzazepines; Chimera; Depression; Drug Partial Agonism; Male; Mice; Mood Disorders; Nicotine; Nicotinic Agonists; Pyridines; Quinoxalines; Varenicline | 2010 |
Varenicline and mecamylamine attenuate locomotor sensitization and cross-sensitization induced by nicotine and morphine in mice.
Topics: Analgesics, Opioid; Animals; Benzazepines; Dose-Response Relationship, Drug; Drug Interactions; Male; Mecamylamine; Mice; Morphine; Motor Activity; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Quinoxalines; Varenicline | 2010 |
Current treatment options in smoking cessation.
Topics: Adrenergic alpha-Agonists; Antidepressive Agents; Behavior Therapy; Benzazepines; Bupropion; Clonidine; Combined Modality Therapy; Counseling; Humans; Nicotine; Nicotinic Agonists; Nortriptyline; Patient Selection; Piperidines; Practice Guidelines as Topic; Pyrazoles; Quinoxalines; Rimonabant; Self-Help Groups; Smoking Cessation; Tobacco Use Disorder; United States; Vaccines; Varenicline | 2010 |
The use of snus for quitting smoking compared with medicinal products.
Topics: Adult; Benzazepines; Chewing Gum; Data Collection; Humans; Male; Middle Aged; Nicotine; Quinoxalines; Regression Analysis; Smoking Cessation; Tobacco, Smokeless; Varenicline | 2010 |
[The management of patients with nicotine dependence - the role of the general practitioners].
Topics: Behavior Therapy; Benzazepines; Bupropion; Combined Modality Therapy; Disease Management; Dopamine Uptake Inhibitors; Family Practice; Humans; Motivation; Nicotine; Nicotinic Agonists; Physician-Patient Relations; Quinoxalines; Secondary Prevention; Smoking Cessation; Switzerland; Tobacco Use Disorder; Varenicline | 2010 |
[Medical therapy for smoking cessation].
Topics: Administration, Cutaneous; Administration, Inhalation; Administration, Oral; Antidepressive Agents; Benzazepines; Bupropion; Chewing Gum; Drug Therapy, Combination; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Tobacco Use Disorder; Varenicline | 2010 |
Varenicline blocks nicotine intake in rats with extended access to nicotine self-administration.
Topics: Animals; Benzazepines; Dose-Response Relationship, Drug; Male; Motivation; Nicotine; Nicotinic Agonists; Quinoxalines; Rats; Rats, Wistar; Receptors, Nicotinic; Reinforcement, Psychology; Self Administration; Varenicline | 2011 |
Abstinence and psychological distress in co-morbid smokers using various pharmacotherapies.
Topics: Adult; Aged; Benzazepines; Bupropion; Cohort Studies; Comorbidity; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Nicotine; Quinoxalines; Retrospective Studies; Smoking; Smoking Cessation; Stress, Psychological; Treatment Outcome; Varenicline; Young Adult | 2011 |
The sensitizing effect of acute nicotine on amphetamine-stimulated behavior and dopamine efflux requires activation of β2 subunit-containing nicotinic acetylcholine receptors and glutamate N-methyl-D-aspartate receptors.
Topics: Aconitine; Amphetamine; Animals; Behavior, Animal; Benzazepines; Central Nervous System Stimulants; Dizocilpine Maleate; Dopamine; Excitatory Amino Acid Antagonists; Female; Male; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Receptors, Nicotinic; Varenicline | 2011 |
Parallel anxiolytic-like effects and upregulation of neuronal nicotinic acetylcholine receptors following chronic nicotine and varenicline.
Topics: Animals; Benzazepines; Cerebral Cortex; Hippocampus; Male; Mice; Nicotine; Quinoxalines; Receptors, Nicotinic; Smoking Cessation; Substance Withdrawal Syndrome; Thalamus; Up-Regulation; Varenicline | 2011 |
Adherence to and reasons for premature discontinuation from stop-smoking medications: data from the ITC Four-Country Survey.
Topics: Adolescent; Adult; Aged; Australia; Benzazepines; Bupropion; Canada; Cohort Studies; Data Collection; Female; Humans; Male; Medication Adherence; Middle Aged; Nicotine; Nonprescription Drugs; Prescription Drugs; Prevalence; Quinoxalines; Smoking Cessation; Time Factors; Tobacco Use Disorder; Treatment Outcome; United Kingdom; United States; Varenicline; Young Adult | 2011 |
The effects of nicotine, varenicline, and cytisine on schedule-controlled responding in mice: differences in α4β2 nicotinic receptor activation.
Topics: Alkaloids; Animals; Azocines; Benzazepines; Conditioning, Operant; Dihydro-beta-Erythroidine; Dose-Response Relationship, Drug; Injections, Intraperitoneal; Male; Mecamylamine; Mice; Mice, Inbred C57BL; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Quinolizines; Quinoxalines; Receptors, Nicotinic; Reinforcement Schedule; Smoking Cessation; Time Factors; Varenicline | 2011 |
Integrating results from smoking cessation drug research and development into clinical occupational health practice.
Topics: Benzazepines; Bupropion; Humans; Nicotine; Nicotinic Agonists; Occupational Health Nursing; Practice Guidelines as Topic; Quinoxalines; Smoking Cessation; Tobacco Use Disorder; Varenicline | 2011 |
Electrophysiological perspectives on the therapeutic use of nicotinic acetylcholine receptor partial agonists.
Topics: Acetylcholine; Alkaloids; alpha7 Nicotinic Acetylcholine Receptor; Animals; Azocines; Benzazepines; Bupropion; DNA, Complementary; Dopamine Uptake Inhibitors; Electrophysiological Phenomena; Humans; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Oocytes; Pyridinium Compounds; Quinolizines; Quinoxalines; Receptors, Nicotinic; Smoking Cessation; Varenicline; Xenopus | 2011 |
Varenicline attenuates cue-induced relapse to alcohol, but not nicotine seeking, while reducing inhibitory response control.
Topics: Animals; Behavior, Animal; Benzazepines; Conditioning, Operant; Cues; Dose-Response Relationship, Drug; Ethanol; Male; Nicotine; Nicotinic Agonists; Quinoxalines; Rats; Rats, Wistar; Reaction Time; Recurrence; Reinforcement Schedule; Self Administration; Sucrose; Varenicline | 2011 |
Selective α4β2 nicotinic acetylcholine receptor agonists target epigenetic mechanisms in cortical GABAergic neurons.
Topics: Analysis of Variance; Animals; Azetidines; Behavior, Animal; Benzazepines; Cerebral Cortex; Conditioning, Classical; Cues; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Epigenomics; Exploratory Behavior; Fear; Freezing Reaction, Cataleptic; gamma-Aminobutyric Acid; Gene Expression Regulation; Glutamate Decarboxylase; Male; Mecamylamine; Methyl-CpG-Binding Protein 2; Mice; Neurons; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Promoter Regions, Genetic; Quinoxalines; Receptors, Nicotinic; RNA, Messenger; Varenicline | 2011 |
[Abstinence rates with varenicline compared to bupropion and nicotine replacement therapy for quitting smoking in primary care].
Topics: Adolescent; Adult; Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Female; Humans; Longitudinal Studies; Male; Middle Aged; Nicotine; Nicotinic Agonists; Primary Health Care; Quinoxalines; Retrospective Studies; Smoking Cessation; Substance Withdrawal Syndrome; Varenicline; Young Adult | 2011 |
Varenicline, a partial agonist at neuronal nicotinic acetylcholine receptors, reduces nicotine-induced increases in 20% ethanol operant self-administration in Sprague-Dawley rats.
Topics: Alcohol Drinking; Animals; Benzazepines; Choice Behavior; Conditioning, Operant; Dose-Response Relationship, Drug; Male; Neurons; Nicotine; Nicotinic Agonists; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Self Administration; Stimulation, Chemical; Varenicline | 2011 |
Prescribing of smoking cessation medication in England since the introduction of varenicline.
Topics: Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Drug Prescriptions; Electronic Health Records; England; Family Practice; Humans; Models, Statistical; Nicotine; Nicotinic Agonists; Practice Guidelines as Topic; Practice Patterns, Physicians'; Quinoxalines; Smoking; Smoking Cessation; Smoking Prevention; State Medicine; Time Factors; Varenicline | 2011 |
Smoking cessation interventions: a primer for physicians: Comment on "Use of varenicline for 4 weeks before quitting smoking".
Topics: Benzazepines; Bupropion; Chewing Gum; Counseling; Delayed-Action Preparations; Drug Administration Schedule; Drug Therapy, Combination; Humans; Nasal Sprays; Nebulizers and Vaporizers; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Smoking Prevention; Substance Withdrawal Syndrome; Time Factors; Transdermal Patch; Treatment Outcome; Varenicline | 2011 |
A comparison of brain and behavioral effects of varenicline and nicotine in rats.
Topics: Animals; Benzazepines; Brain; Brain Mapping; Drug Administration Schedule; Drug Tolerance; Injections, Intravenous; Injections, Subcutaneous; Magnetic Resonance Imaging; Male; Maze Learning; Motor Activity; Nicotine; Nicotinic Agonists; Quinoxalines; Rats; Rats, Sprague-Dawley; Varenicline | 2011 |
Cost effectiveness of interventions to reduce relapse to smoking following smoking cessation.
Topics: Benzazepines; Bupropion; Cost-Benefit Analysis; Dopamine Uptake Inhibitors; England; Epidemiologic Methods; Health Care Costs; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; Secondary Prevention; Smoking; Smoking Cessation; Treatment Outcome; Varenicline; Wales | 2011 |
The impact of the introduction of smoke-free legislation on prescribing of stop-smoking medications in England.
Topics: Adolescent; Adult; Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Drug Prescriptions; Electronic Health Records; England; Family Practice; Female; Humans; Male; Middle Aged; Models, Statistical; Nicotine; Nicotinic Agonists; Practice Patterns, Physicians'; Quinoxalines; Smoking; Smoking Cessation; State Medicine; Time Factors; Varenicline; Young Adult | 2011 |
Smoking cessation pharmacotherapy: a concise overview.
Topics: Adrenergic alpha-2 Receptor Agonists; Antidepressive Agents; Benzazepines; Bupropion; Clonidine; Humans; Nicotine; Nicotinic Agonists; Nortriptyline; Quinoxalines; Smoking; Smoking Cessation; Varenicline | 2011 |
Assessing preferences for improved smoking cessation medications: a discrete choice experiment.
Topics: Adolescent; Adult; Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Female; Humans; Logistic Models; Male; Middle Aged; Models, Econometric; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Substance-Related Disorders; Surveys and Questionnaires; Switzerland; Varenicline; Young Adult | 2012 |
Patterns of nicotinic receptor antagonism: nicotine discrimination studies.
Topics: Animals; Benzazepines; Bridged Bicyclo Compounds, Heterocyclic; Cytosine; Data Interpretation, Statistical; Dihydro-beta-Erythroidine; Discrimination Learning; Discrimination, Psychological; Dose-Response Relationship, Drug; Male; Mecamylamine; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Pyridines; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Varenicline | 2011 |
Breaking free from nicotine dependence. A combination of strategies boosts the odds of success.
Topics: Administration, Cutaneous; Administration, Intranasal; Adult; Antidepressive Agents, Second-Generation; Behavior Therapy; Benzazepines; Bupropion; Cognitive Behavioral Therapy; Cross-Sectional Studies; Female; Humans; Male; Nicotine; Nicotinic Agonists; Quinoxalines; Self-Help Groups; Smoking Cessation; Tobacco Use Disorder; Varenicline | 2011 |
Effects of varenicline on the reinforcing and discriminative stimulus effects of cocaine in rhesus monkeys.
Topics: Animals; Benzazepines; Cocaine; Cocaine-Related Disorders; Conditioning, Operant; Discrimination Learning; Discrimination, Psychological; Dopamine Uptake Inhibitors; Macaca mulatta; Male; Mecamylamine; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Quinoxalines; Reinforcement, Psychology; Self Administration; Time Factors; Varenicline | 2011 |
Nicotinic excitatory postsynaptic potentials in hippocampal CA1 interneurons are predominantly mediated by nicotinic receptors that contain α4 and β2 subunits.
Topics: 2-Amino-5-phosphonovalerate; Acetylcholine; Aconitine; Animals; Biophysics; CA1 Region, Hippocampal; Channelrhodopsins; Cholinergic Fibers; Diagonal Band of Broca; Dihydro-beta-Erythroidine; Electric Stimulation; Excitatory Amino Acid Antagonists; Excitatory Postsynaptic Potentials; In Vitro Techniques; Interneurons; Light; Mice; Neural Pathways; Nicotine; Nicotinic Antagonists; Optics and Photonics; Patch-Clamp Techniques; Quinoxalines; Receptors, Nicotinic; Transduction, Genetic; Voltage-Sensitive Dye Imaging | 2011 |
[Clinical study of smoking cessation clinic subjects].
Topics: Adult; Aged; Aged, 80 and over; Benzazepines; Female; Humans; Male; Middle Aged; Nicotine; Nicotinic Agonists; Outpatient Clinics, Hospital; Outpatients; Quinoxalines; Smoking Cessation; Varenicline | 2011 |
Varenicline decreases nicotine self-administration and cue-induced reinstatement of nicotine-seeking behaviour in rats when a long pretreatment time is used.
Topics: Animals; Benzazepines; Conditioning, Operant; Cues; Data Interpretation, Statistical; Discrimination, Psychological; Dose-Response Relationship, Drug; Drug-Seeking Behavior; Feeding Behavior; Male; Motivation; Nicotine; Quinoxalines; Rats; Rats, Long-Evans; Rats, Sprague-Dawley; Reinforcement Schedule; Self Administration; Tobacco Use Disorder; Varenicline | 2012 |
[Smoking cessation--assistance for the general practitioner].
Topics: Benzazepines; Bupropion; Combined Modality Therapy; Complementary Therapies; Cost-Benefit Analysis; Drug Costs; Fee Schedules; Germany; Humans; Myocardial Infarction; National Health Programs; Nicotine; Nicotinic Agonists; Physician's Role; Polymethacrylic Acids; Polyvinyls; Psychotherapy, Group; Quinoxalines; Smoking Cessation; Social Support; Tobacco Use Cessation Devices; Tobacco Use Disorder; Varenicline | 2011 |
Varenicline dose dependently enhances responding for nonpharmacological reinforcers and attenuates the reinforcement-enhancing effects of nicotine.
Topics: Animals; Benzazepines; Dose-Response Relationship, Drug; Male; Nicotine; Nicotinic Agonists; Quinoxalines; Rats; Rats, Sprague-Dawley; Reinforcement, Psychology; Smoking Cessation; Tobacco Use Disorder; Varenicline | 2012 |
Quantification of nicotine, cotinine, trans-3'-hydroxycotinine and varenicline in human plasma by a sensitive and specific UPLC-tandem mass-spectrometry procedure for a clinical study on smoking cessation.
Topics: Benzazepines; Chromatography, High Pressure Liquid; Cotinine; Drug Stability; Humans; Linear Models; Nicotine; Quinoxalines; Reproducibility of Results; Sensitivity and Specificity; Smoking Cessation; Tandem Mass Spectrometry; Varenicline | 2011 |
Suicidal behavior and depression in smoking cessation treatments.
Topics: Adult; Benzazepines; Bupropion; Depression; Female; Humans; Male; Middle Aged; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Suicide; Varenicline | 2011 |
Varenicline blocks β2*-nAChR-mediated response and activates β4*-nAChR-mediated responses in mice in vivo.
Topics: Animals; Benzazepines; Dose-Response Relationship, Drug; Female; Genotype; Hexamethonium; Hypothermia; Inhibitory Concentration 50; Male; Mecamylamine; Mice; Mice, Inbred C57BL; Motor Activity; Mutation; Nerve Tissue Proteins; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Ondansetron; Quinoxalines; Receptors, Nicotinic; Receptors, Serotonin, 5-HT3; Varenicline | 2012 |
Effects of the combination of metyrapone and oxazepam on intravenous nicotine self-administration in rats.
Topics: Animals; Benzazepines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enzyme Inhibitors; Hypnotics and Sedatives; Infusions, Intravenous; Male; Metyrapone; Nicotine; Oxazepam; Quinoxalines; Rats; Rats, Wistar; Reinforcement Schedule; Self Administration; Smoking Cessation; Varenicline | 2012 |
Pharmacologic characterization of a nicotine-discriminative stimulus in rhesus monkeys.
Topics: Alkaloids; Animals; Azocines; Benzazepines; Cocaine; Conditioning, Operant; Discrimination Learning; Dopamine Uptake Inhibitors; Drug Interactions; Female; Hypnotics and Sedatives; Macaca mulatta; Male; Mecamylamine; Midazolam; Nicotine; Nicotinic Agonists; Quinolizines; Quinoxalines; Receptors, Nicotinic; Varenicline | 2012 |
An internet survey of use, opinions and preferences for smoking cessation medications: nicotine, varenicline, and bupropion.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Benzazepines; Bupropion; Data Collection; Educational Status; Female; Humans; Internet; Male; Middle Aged; Nicotine; Patient Compliance; Patient Satisfaction; Quinoxalines; Smoking Cessation; Tobacco Use Cessation Devices; Varenicline; Young Adult | 2013 |
Varenicline is a potent partial agonist at α6β2* nicotinic acetylcholine receptors in rat and monkey striatum.
Topics: Animals; Benzazepines; Corpus Striatum; Dopamine; Male; Nicotine; Protein Binding; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Saimiri; Smoking Cessation; Synaptosomes; Varenicline | 2012 |
Structural characterization of binding mode of smoking cessation drugs to nicotinic acetylcholine receptors through study of ligand complexes with acetylcholine-binding protein.
Topics: Acetylcholine; Alkaloids; alpha7 Nicotinic Acetylcholine Receptor; Animals; Aplysia; Azocines; Benzazepines; Binding Sites; Binding, Competitive; Carrier Proteins; Cell Line; HEK293 Cells; Humans; Kinetics; Ligands; Models, Molecular; Mutation; Nicotine; Nicotinic Agonists; Protein Binding; Protein Structure, Secondary; Protein Structure, Tertiary; Quinolizines; Quinoxalines; Receptors, Nicotinic; Smoking Cessation; Varenicline | 2012 |
Use of an α3β4 nicotinic acetylcholine receptor subunit concatamer to characterize ganglionic receptor subtypes with specific subunit composition reveals species-specific pharmacologic properties.
Topics: Acetylcholine; Alkaloids; Animals; Azocines; Benzazepines; Drug Partial Agonism; Evoked Potentials; Ganglia; Humans; Ligands; Mutagenesis, Site-Directed; Mutant Proteins; Nerve Tissue Proteins; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Oocytes; Protein Subunits; Quinolizines; Quinoxalines; Rats; Receptors, Nicotinic; Recombinant Fusion Proteins; Species Specificity; Varenicline; Xenopus laevis | 2012 |
Impact of human D398N single nucleotide polymorphism on intracellular calcium response mediated by α3β4α5 nicotinic acetylcholine receptors.
Topics: Acetylcholine; Aequorin; Algorithms; Benzazepines; Calcium; Data Interpretation, Statistical; Enzyme-Linked Immunosorbent Assay; HEK293 Cells; Humans; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Permeability; Polymorphism, Single Nucleotide; Quinoxalines; Receptors, Nicotinic; Varenicline | 2012 |
Chronic sazetidine-A at behaviorally active doses does not increase nicotinic cholinergic receptors in rodent brain.
Topics: Animals; Azetidines; Behavior, Animal; Benzazepines; Binding Sites; Brain Chemistry; Cerebral Cortex; Dose-Response Relationship, Drug; Female; Male; Membranes; Neurons; Nicotine; Nicotinic Agonists; Pregnancy; Pyridines; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Self Administration; Up-Regulation; Varenicline | 2012 |
Effects of nicotinic acetylcholine receptor agonists on cognition in rhesus monkeys with a chronic cocaine self-administration history.
Topics: Animals; Behavior, Animal; Benzamides; Benzazepines; Bridged Bicyclo Compounds; Cocaine; Cocaine-Related Disorders; Cognition Disorders; Dopamine Uptake Inhibitors; Hippocampus; Learning; Ligands; Macaca mulatta; Male; Memory, Short-Term; Nerve Tissue Proteins; Neurons; Nicotine; Nicotinic Agonists; Nootropic Agents; Quinoxalines; Receptors, Nicotinic; Reversal Learning; Self Administration; Varenicline | 2013 |
The effect of smoking cessation pharmacotherapies on pancreatic beta cell function.
Topics: Animals; Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Electron Transport; Gene Expression; Glucose; Insulin; Insulin Secretion; Insulin-Secreting Cells; Mitochondria; Nicotine; Nicotinic Agonists; Oxidative Stress; Pancreatic Function Tests; Quinoxalines; Rats; Signal Transduction; Smoking; Smoking Cessation; Varenicline | 2012 |
Varenicline and bupropion: suicide.
Topics: Benzazepines; Bupropion; Humans; Nicotine; Nicotinic Agonists; Patient Safety; Prescription Drug Misuse; Quinoxalines; Risk Assessment; Risk Factors; Smoking Cessation; Suicide; Varenicline | 2012 |
Involvement of cholinergic receptors in the different stages of memory measured in the modified elevated plus maze test in mice.
Topics: Animals; Benzazepines; Male; Maze Learning; Mecamylamine; Memory; Mice; Motor Activity; Nicotine; Quinoxalines; Receptors, Cholinergic; Scopolamine; Varenicline | 2012 |
Involvement of NMDA receptors in nicotine-mediated central control of hypotensive effects.
Topics: Animals; Blood Pressure; Bradycardia; Dizocilpine Maleate; Drug Interactions; Excitatory Amino Acid Antagonists; Glutamic Acid; Heart Rate; Hypotension; Male; Nicotine; Nicotinic Agonists; Quinoxalines; Rats; Rats, Inbred WKY; Receptors, N-Methyl-D-Aspartate; Signal Transduction; Solitary Nucleus; Valine | 2012 |
Nicotine-motivated behavior in Caenorhabditis elegans requires the nicotinic acetylcholine receptor subunits acr-5 and acr-15.
Topics: Age Factors; Animals; Behavior, Animal; Benzazepines; Butanones; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Chemotaxis; Chlorides; Fasting; Mecamylamine; Muscles; Mutation; Neurons; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Protein Subunits; Quinoxalines; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Nicotinic; Reward; Sodium; Taste; Time Factors; Varenicline | 2013 |
Varenicline and nicotine enhance GABAergic synaptic transmission in rat CA1 hippocampal and medial septum/diagonal band neurons.
Topics: Animals; Benzazepines; CA1 Region, Hippocampal; Female; GABAergic Neurons; Inhibitory Postsynaptic Potentials; Male; Neural Inhibition; Neurons; Nicotine; Nicotinic Agonists; Patch-Clamp Techniques; Quinoxalines; Rats; Rats, Sprague-Dawley; Septal Nuclei; Synaptic Transmission; Varenicline | 2013 |
Layer-specific interference with cholinergic signaling in the prefrontal cortex by smoking concentrations of nicotine.
Topics: Acetylcholine; Action Potentials; alpha7 Nicotinic Acetylcholine Receptor; Analysis of Variance; Animals; Animals, Newborn; Bicuculline; Calcium; Cholinesterase Inhibitors; Dihydro-beta-Erythroidine; Dose-Response Relationship, Drug; Electric Stimulation; Excitatory Amino Acid Antagonists; GABA-A Receptor Antagonists; Galantamine; In Vitro Techniques; Mice; Mice, Inbred C57BL; Nerve Net; Neurons; Nicotine; Nicotinic Agonists; Patch-Clamp Techniques; Prefrontal Cortex; Quinoxalines; Receptors, Nicotinic; Signal Transduction | 2013 |
Multiple nicotine training doses in mice as a basis for differentiating the effects of smoking cessation aids.
Topics: Alkaloids; Animals; Azocines; Benzazepines; Dihydro-beta-Erythroidine; Discrimination Learning; Dose-Response Relationship, Drug; Male; Mecamylamine; Mice; Mice, Inbred C57BL; Midazolam; Morphine; Nicotine; Nicotinic Agonists; Quinolizines; Quinoxalines; Receptors, Nicotinic; Smoking Cessation; Tobacco Use Cessation Devices; Varenicline | 2013 |
Divergent functional effects of sazetidine-a and varenicline during nicotine withdrawal.
Topics: Animals; Anxiety; Azetidines; Benzazepines; Cerebral Cortex; Dose-Response Relationship, Drug; Drug Partial Agonism; Evoked Potentials; Hippocampus; Male; Mice; Microinjections; Motor Activity; Nicotine; Nicotinic Agonists; Pyridines; Quinoxalines; Receptors, Nicotinic; Smoking Cessation; Substance Withdrawal Syndrome; Up-Regulation; Varenicline | 2013 |
Neuronal nicotinic receptor agonists improve gait and balance in olivocerebellar ataxia.
Topics: Animals; Ataxia; Benzazepines; Cerebellum; Dose-Response Relationship, Drug; Gait; Male; Mecamylamine; Motor Activity; Nerve Degeneration; Neural Pathways; Niacinamide; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Olivary Nucleus; Postural Balance; Pyridines; Quinoxalines; Rats; Rotarod Performance Test; Varenicline | 2013 |
PET imaging of high-affinity α4β2 nicotinic acetylcholine receptors in humans with 18F-AZAN, a radioligand with optimal brain kinetics.
Topics: 2,2'-Dipyridyl; Adult; Animals; Azabicyclo Compounds; Benzazepines; Binding, Competitive; Brain; Female; Humans; Kinetics; Ligands; Male; Middle Aged; Nicotine; Nicotinic Agonists; Papio; Positron-Emission Tomography; Quinoxalines; Radiometry; Receptors, Nicotinic; Reproducibility of Results; Varenicline | 2013 |
Effectiveness of varenicline versus nicotine replacement therapy for smoking cessation with minimal professional support: evidence from an English population study.
Topics: Adult; Aged; Benzazepines; Cross-Sectional Studies; Data Collection; Data Interpretation, Statistical; England; Female; Humans; Male; Middle Aged; Nicotine; Nicotinic Agonists; Population; Prescription Drugs; Quinoxalines; Smoking; Smoking Cessation; Treatment Outcome; Varenicline | 2014 |
Varenicline and cytisine diminish the dysphoric-like state associated with spontaneous nicotine withdrawal in rats.
Topics: Alkaloids; Animals; Azocines; Benzazepines; Infusion Pumps, Implantable; Male; Nicotine; Nicotinic Agonists; Quinolizines; Quinoxalines; Rats; Rats, Wistar; Substance Withdrawal Syndrome; Varenicline | 2014 |
Effect of allopurinol on smoking.
Topics: Acetylcholine; Allopurinol; Benzazepines; Brain Chemistry; Bupropion; Causality; Comorbidity; Diabetic Nephropathies; Humans; Hypoxanthine; Molecular Structure; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Structure-Activity Relationship; Varenicline; Xanthine Oxidase | 2013 |
The effect of varenicline on the development and expression of nicotine-induced behavioral sensitization and cross-sensitization in rats.
Topics: Animals; Benzazepines; Motor Activity; Nicotine; Nicotinic Agonists; Quinoxalines; Rats; Smoking Cessation; Varenicline | 2015 |
Effects of chronic varenicline treatment on nicotine, cocaine, and concurrent nicotine+cocaine self-administration.
Topics: Animals; Benzazepines; Cocaine; Cocaine-Related Disorders; Conditioning, Operant; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug-Seeking Behavior; Feeding Behavior; Female; Macaca mulatta; Male; Motivation; Nicotine; Nicotinic Agonists; Quinoxalines; Reinforcement, Psychology; Self Administration; Tobacco Use Disorder; Varenicline | 2014 |
Functional interactions of varenicline and nicotine with nAChR subtypes implicated in cardiovascular control.
Topics: Animals; Benzazepines; Humans; Nicotine; Nicotinic Agonists; Oocytes; Protein Binding; Quinoxalines; Receptors, Nicotinic; Tobacco Use Disorder; Varenicline; Xenopus laevis | 2014 |
Chronic sazetidine-A maintains anxiolytic effects and slower weight gain following chronic nicotine without maintaining increased density of nicotinic receptors in rodent brain.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Azetidines; Benzazepines; Brain Chemistry; Drug Evaluation, Preclinical; Feeding Behavior; Gene Expression Regulation; Male; Mice; Mice, Inbred C57BL; Nicotine; Nicotinic Agonists; Pyridines; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Substance Withdrawal Syndrome; Tobacco Use Cessation; Tobacco Use Disorder; Up-Regulation; Varenicline; Weight Gain | 2014 |
[Safety of nicotine addiction treatment].
Topics: Abdominal Pain; Adult; Alkaloids; Azocines; Benzazepines; Boredom; Bupropion; Female; Headache; Humans; Male; Middle Aged; Nicotine; Patient Compliance; Quinolizines; Quinoxalines; Sleep Wake Disorders; Smoking Cessation; Tobacco Use Disorder; Varenicline; Xerostomia | 2013 |
Varenicline disrupts prepulse inhibition only in high-inhibitory rats.
Topics: Acoustic Stimulation; Acoustics; Analysis of Variance; Animals; Apomorphine; Benzazepines; Dizocilpine Maleate; Dopamine Agonists; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Male; Nicotine; Nicotinic Agonists; Prepulse Inhibition; Quinoxalines; Rats; Rats, Sprague-Dawley; Reflex, Startle; Varenicline | 2014 |
Larval zebrafish model for FDA-approved drug repositioning for tobacco dependence treatment.
Topics: Animals; Benzazepines; Drug Repositioning; Models, Animal; Nicotine; Quinoxalines; Tobacco Use Disorder; United States; United States Food and Drug Administration; Varenicline; Zebrafish | 2014 |
The cytisine derivatives, CC4 and CC26, reduce nicotine-induced conditioned place preference in zebrafish by acting on heteromeric neuronal nicotinic acetylcholine receptors.
Topics: Alkaloids; Animals; Benzazepines; Conditioning, Operant; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Quinoxalines; Receptors, Nicotinic; Varenicline; Zebrafish | 2014 |
Differentiating the primary reinforcing and reinforcement-enhancing effects of varenicline.
Topics: Animals; Benzazepines; Conditioning, Operant; Cues; Dose-Response Relationship, Drug; Male; Nicotine; Nicotinic Agonists; Quinoxalines; Rats; Rats, Sprague-Dawley; Reinforcement Schedule; Reinforcement, Psychology; Self Administration; Smoking Cessation; Varenicline | 2015 |
Examination of the effects of varenicline, bupropion, lorcaserin, or naltrexone on responding for conditioned reinforcement in nicotine-exposed rats.
Topics: Animals; Benzazepines; Bupropion; Cholinergic Agents; Conditioning, Operant; Dose-Response Relationship, Drug; Drug Interactions; Male; Naltrexone; Narcotic Antagonists; Nicotine; Quinoxalines; Rats; Rats, Long-Evans; Reinforcement, Psychology; Varenicline | 2014 |
Concurrent access to nicotine and sucrose in rats.
Topics: Animals; Behavior, Addictive; Benzazepines; Conditioning, Operant; Male; Nicotine; Quinoxalines; Rats; Rats, Sprague-Dawley; Reinforcement, Psychology; Self Administration; Sucrose; Varenicline | 2015 |
Prospective cohort study of the effectiveness of varenicline versus nicotine replacement therapy for smoking cessation in the "real world".
Topics: Adolescent; Adult; Benzazepines; Cohort Studies; Cross-Sectional Studies; Female; Humans; Longitudinal Studies; Male; Middle Aged; Netherlands; Nicotine; Nicotinic Agonists; Patient Compliance; Prospective Studies; Quinoxalines; Smoking Cessation; Surveys and Questionnaires; Treatment Outcome; Varenicline | 2014 |
Gender differences in medication use and cigarette smoking cessation: results from the International Tobacco Control Four Country Survey.
Topics: Adolescent; Adult; Australia; Benzazepines; Canada; Female; Gender Identity; Humans; Longitudinal Studies; Male; Middle Aged; Motivation; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Smoking Prevention; Substance Withdrawal Syndrome; United Kingdom; United States; Varenicline | 2015 |
Early postnatal nicotine exposure disrupts the α2* nicotinic acetylcholine receptor-mediated control of oriens-lacunosum moleculare cells during adolescence in rats.
Topics: Age Factors; Animals; Animals, Newborn; Bicuculline; Excitatory Amino Acid Antagonists; Female; GABA-A Receptor Antagonists; Gene Expression Regulation, Developmental; Hippocampus; In Vitro Techniques; Interneurons; Long-Term Potentiation; Male; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Patch-Clamp Techniques; Pregnancy; Prenatal Exposure Delayed Effects; Quinoxalines; Rats; Rats, Sprague-Dawley; Valine | 2016 |
Nicotinic activity depresses synaptic potentiation in layer V pyramidal neurons of mouse insular cortex.
Topics: Acetylcholine; Animals; Animals, Newborn; Bicuculline; Cerebral Cortex; Cholinergic Agents; Dihydro-beta-Erythroidine; Excitatory Amino Acid Antagonists; Female; GABA-A Receptor Antagonists; Lysine; Male; Mice; Mice, Inbred C57BL; Neural Inhibition; Nicotine; Pyramidal Cells; Quinoxalines; Synaptic Potentials; Valine | 2017 |
NBQX attenuates relapse of nicotine seeking but not nicotine and methamphetamine self-administration in rats.
Topics: Animals; Dose-Response Relationship, Drug; Male; Methamphetamine; Nicotine; Quinoxalines; Rats; Rats, Wistar; Recurrence; Self Administration | 2021 |
Characterising the use of varenicline: an analysis of the Australian dispensing claims data.
Topics: Aged; Australia; Benzazepines; Bupropion; Humans; Male; Nicotine; Nicotinic Agonists; Quinoxalines; Retrospective Studies; Smoking; Smoking Cessation; Tobacco Use Cessation Devices; Varenicline | 2022 |
[Tobacco cessation treatment for people with schizophrenia].
Topics: Benzazepines; Bupropion; Humans; Nicotine; Quinoxalines; Schizophrenia; Smoking Cessation; Tobacco Use Cessation; Tobacco Use Cessation Devices; Varenicline | 2022 |
Varenicline serves as the training stimulus in the drug-discriminated goal-tracking task with rats: initial evaluation of potential neuropharmacological processes.
Topics: Animals; Benzazepines; Bupropion; Goals; Motivation; Nicotine; Nicotinic Agonists; Quinoxalines; Rats; Receptors, Nicotinic; Smoking Cessation Agents; Varenicline | 2023 |
Nicotine and Cytisine Embryotoxicity in the Experimental Zebrafish Model.
Topics: Alkaloids; Animals; Azocines; Benzazepines; Humans; Nicotine; Nicotinic Agonists; Quinolizines; Quinoxalines; Receptors, Nicotinic; Varenicline; Zebrafish | 2023 |